<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Catheter-related upper extremity venous thrombosis in adults</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Catheter-related upper extremity venous thrombosis in adults</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Catheter-related upper extremity venous thrombosis in adults</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Vineet Chopra, MD, MSc</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Ingemar Davidson, MD, PhD, FACS</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Amalia Cochran, MD, FACS, FCCM</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Kathryn A Collins, MD, PhD, FACS</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Sep 01, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Intravenous catheters cause endothelial trauma and inflammation and are often placed in patients who are hypercoagulable, leading to venous thrombosis. The majority (70 to 80 percent) of thrombotic events occurring in the superficial and deep veins of the upper extremity are due to intravenous catheters. The remainder are due to mechanical compression from anatomic abnormalities (eg, venous thoracic outlet syndrome) [<a href="#rid1">1-3</a>].</p><p>While superficial vein thrombosis and phlebitis related to peripheral intravenous catheters are generally self-limited once the catheter is removed, these patients can develop deep vein thrombosis (DVT) with its attendant risk for embolism. Thrombosis involving the deep veins of the upper extremity (axillary, brachial) or thoracic central veins (ie, subclavian, brachiocephalic, superior vena cava, intrathoracic internal jugular vein) can lead to pulmonary embolism and long-term sequelae in spite of timely diagnosis and treatment [<a href="#rid4">4,5</a>]. Pulmonary embolism from upper extremity sources accounts for approximately 6 percent of cases [<a href="#rid6">6-8</a>].</p><p>Upper extremity venous thrombosis (superficial and deep) as a complication of indwelling venous catheters is reviewed. Thrombosis involving the <strong>lower </strong>extremity veins is discussed elsewhere. (See  <a class="medical medical_review" href="/d/html/8199.html" rel="external">"Superficial vein thrombosis and phlebitis of the lower extremity veins"</a> and  <a class="medical medical_review" href="/d/html/1351.html" rel="external">"Clinical presentation and diagnosis of the nonpregnant adult with suspected deep vein thrombosis of the lower extremity"</a>.)</p><p>General issues regarding DVT, primary causes of upper extremity DVT, and thrombosis related to hemodialysis access are also discussed elsewhere. (See  <a class="medical medical_review" href="/d/html/1361.html" rel="external">"Overview of the causes of venous thrombosis"</a> and  <a class="medical medical_review" href="/d/html/8211.html" rel="external">"Primary (spontaneous) upper extremity deep vein thrombosis"</a> and  <a class="medical medical_review" href="/d/html/1843.html" rel="external">"Central venous catheters for acute and chronic hemodialysis access and their management"</a>.) </p><p>Other complications of central venous catheters and the approach to catheter selection, including in those patients who have experienced a prior catheter thrombosis, are reviewed separately. (See  <a class="medical medical_review" href="/d/html/8180.html" rel="external">"Central venous catheters: Overview of complications and prevention in adults"</a> and  <a class="medical medical_review" href="/d/html/115957.html" rel="external">"Central venous access: Device and site selection in adults"</a>.)</p><p class="headingAnchor" id="H2279365840"><span class="h1">ANATOMIC CONSIDERATIONS</span><span class="headingEndMark"> — </span>Venous catheters can be placed into the superficial or deep veins of the upper extremity, and for central catheters, centrally or peripherally. Detailed anatomy is described separately. (See  <a class="medical medical_review" href="/d/html/15672.html" rel="external">"Placement of jugular venous catheters", section on 'Jugular vein anatomy'</a> and  <a class="medical medical_review" href="/d/html/15673.html" rel="external">"Placement of subclavian venous catheters", section on 'Subclavian vein anatomy'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>Superficial — The main superficial veins of the upper extremity include the cephalic, basilic, median antebrachial, median antecubital, and accessory cephalic veins  (<a class="graphic graphic_figure graphicRef55596" href="/d/graphic/55596.html" rel="external">figure 1</a> and <a class="graphic graphic_figure graphicRef126101" href="/d/graphic/126101.html" rel="external">figure 2</a>) [<a href="#rid9">9</a>]. There is considerable anatomic variation. Peripheral intravenous catheters are typically placed into the superficial veins of the forearm or hand, but the external jugular vein is a common access site during anesthesia. The basilic vein is one of the most common access sites used for placement of peripherally inserted central catheters</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Deep — The deep veins of the upper extremity include the paired ulnar, radial, and interosseous veins in the forearm; paired brachial veins of the upper arm; and axillary veins. The internal jugular vein is a deep vein in the neck and a common access site for catheter insertion. The deep veins of the chest (ie, thoracic central veins) include the subclavian veins  (<a class="graphic graphic_figure graphicRef61941" href="/d/graphic/61941.html" rel="external">figure 3</a>), which join the intrathoracic portion of the internal jugular veins to become the brachiocephalic veins, which in turn join together to become the superior vena cava  (<a class="graphic graphic_figure graphicRef81142" href="/d/graphic/81142.html" rel="external">figure 4</a>). </p><p></p><p class="headingAnchor" id="H5"><span class="h1">EPIDEMIOLOGY AND RISK FACTORS</span><span class="headingEndMark"> — </span>For patients with central venous access, a wide variation in the incidence of venous thrombosis (1 to 66 percent) is reported, and the incidence depends upon the catheter type and location, criteria for diagnosis, type of test used, and population studied [<a href="#rid10">10-15</a>]. One retrospective study from a single institution estimated the frequency of thromboembolic disease of the brachiocephalic vein or superior vena cava due to central catheters to be 6 per 10,000 hospital admissions [<a href="#rid11">11</a>]. Although peripherally inserted central catheters (PICCs) reduce the incidence of pneumothorax by avoiding the deep veins of the neck and chest, they appear to have an incidence of upper extremity venous thrombosis that is similar to, if not greater than, that of centrally inserted catheters (CICCs), ranging from 3 to 58 percent [<a href="#rid16">16-20</a>]. In a study of postoperative general surgical patients, 58 percent of deep vein thromboses (DVTs) occurred in the upper extremity, all but one of which was catheter related [<a href="#rid21">21</a>]. </p><p>The most common site of DVT for centrally placed catheters is the internal jugular vein [<a href="#rid22">22</a>]. For PICCs, the brachial, axillary, or subclavian veins are commonly involved. Thus, great caution should be used when considering intravenous access options in patients who may require hemodialysis access in the future due to the relatively high incidence of PICC-associated venous thrombosis. (See <a class="local">'Peripheral versus central insertion'</a> below and  <a class="medical medical_review" href="/d/html/116371.html" rel="external">"Peripherally inserted central catheter (PICC)-related venous thrombosis in adults", section on 'Risk factors'</a>.)</p><p>The highest reported incidences of upper extremity DVT are from studies that systematically screen for thrombus in patients with central catheters (asymptomatic and symptomatic), particularly those with malignancy. In one retrospective review, ultrasound confirmed the presence of upper extremity DVT in 60 percent of patients screened [<a href="#rid12">12</a>]. Another prospective study in patients with malignancy found that 75 percent of patients identified with upper extremity DVT were asymptomatic [<a href="#rid13">13</a>]. </p><p class="headingAnchor" id="H6"><span class="h2">Risk factors</span><span class="headingEndMark"> — </span>Any intravenous catheter has the potential to cause venous thrombosis [<a href="#rid23">23</a>]. These include peripheral intravenous catheters, PICCs [<a href="#rid24">24</a>], and tunneled and nontunneled central catheter port devices [<a href="#rid25">25,26</a>]. (See  <a class="medical medical_review" href="/d/html/115957.html" rel="external">"Central venous access: Device and site selection in adults", section on 'Types of central venous catheters'</a> and  <a class="medical medical_review" href="/d/html/8194.html" rel="external">"Central venous access in adults: General principles", section on 'Central venous access'</a>.)</p><p>An individual patient-level systematic review and meta-analysis identified 425 catheter-related thromboses among 5636 patients with malignancy (7.5 percent) from five trials and seven prospective studies [<a href="#rid27">27</a>]. The use of PICCs, previous history of DVT, subclavian venipuncture insertion site, and improper positioning of the catheter tip were associated with an increased risk for catheter-related thrombosis on multivariate logistic regression. </p><p class="headingAnchor" id="H165302905"><span class="h3">Catheter-related factors</span><span class="headingEndMark"> — </span>Many studies have reported the association of specific catheter-related factors and upper extremity venous thrombosis. </p><p class="headingAnchor" id="H3487410514"><span class="h4">Catheter type</span><span class="headingEndMark"> — </span>The incidence of venous thrombosis is overall lower for port devices, and generally lower compared with PICCs, but increased for those with malignancy [<a href="#rid28">28</a>]. In the above systematic review, the risk of catheter-related thrombosis was lower for implanted ports compared with PICC catheters (odds ratio [OR] 0.43, 95% CI 0.23-0.80) [<a href="#rid27">27</a>]. </p><p class="bulletIndent1"><span class="glyph">●</span>In a review of over 50,000 port devices, the overall risk for port-related venous DVT was at 1.8 percent. However, in a prospective multicenter study of patients with malignancy, ports were associated with a thrombosis rate of 3.8 percent; placement via the cephalic vein was associated with the greatest risk [<a href="#rid28">28</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a subsequent systematic review that included 80 studies, the overall incidence of symptomatic venous thromboembolism was 2.76 percent (95% CI, 2.24-3.28) [<a href="#rid29">29</a>]. A subgroup analysis showed that the odds of venous thrombosis was significantly lower for ports compared with PICCs in patients with malignancy (OR 0.20, 95% CI 0.09-0.43). </p><p></p><p>The reported rates of thrombosis associated with midline catheters are more variable. Differences in midline catheter materials, insertion techniques, types of infusates, care and management of midlines, as well as strategies to diagnose DVT may explain differences in study findings [<a href="#rid30">30</a>]. </p><p class="bulletIndent1"><span class="glyph">●</span>In one review that included over 2500 catheters, midline catheters were associated with an increased risk of thrombosis compared with PICCs (7 versus 4.7 percent) [<a href="#rid31">31</a>]. Whereas, in a multicenter review of 1161 midlines, DVT occurred in 1.4 percent [<a href="#rid32">32</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a multicenter cohort study of hospitalized patients who received PICCs or midlines for the indication of difficult venous access, midlines were associated with similar odds of DVT compared with PICCs (OR 0.93, 95% CI 0.63-1.37). However, DVT events in patients with midlines occurred over a shorter dwell time when compared with PICCs. Thus, when expressed as a hazard ratio, the risk for DVT when comparing midlines with PICCs on a day-to-day basis was greater for midlines (hazard ratio 0.53, 95% CI 0.38-0.74) [<a href="#rid33">33</a>].</p><p></p><p class="headingAnchor" id="H85797994"><span class="h4">Catheter diameter/number of lumens</span><span class="headingEndMark"> — </span>The diameter of the catheter relative to the size of the vein determines whether or not blood will flow freely around the catheter or stagnate [<a href="#rid27">27,34,35</a>]. For a vein of similar size, thrombosis is more likely with a large-diameter, centrally placed catheter (eg, plasmapheresis, dialysis, multilumen catheters) compared with a small-diameter catheter (eg, single lumen). </p><p>As such, for PICCs, insertion is recommended only when the catheter-to-vein ratio does not exceed 45 percent [<a href="#rid19">19,36</a>]. Some studies suggest this ratio should be lowered even further, reaching values of 33 percent [<a href="#rid36">36,37</a>]. In one study involving PICC catheters of varying diameters, 5 and 6 French PICCs were significantly more likely to develop DVT compared with 4 French PICCs [<a href="#rid38">38,39</a>]. In a quality improvement initiative, preferential use of single-lumen PICCs (as recommended by published appropriateness criteria [<a href="#rid40">40</a>]) was associated with a reduction in occlusion and thrombotic complications [<a href="#rid41">41</a>]. For central venous catheters placed into large vessels such as the internal jugular or subclavian veins, the ratio between the catheter to the vessel tends to be more favorable with lower reported rates of thrombosis [<a href="#rid42">42</a>]. </p><p class="headingAnchor" id="H85798006"><span class="h4">Peripheral versus central insertion</span><span class="headingEndMark"> — </span>PICCs appear to be associated with a greater risk for venous thrombosis overall (superficial and deep thrombosis) compared with CICCs, particularly among those who are critically ill or who have malignancy [<a href="#rid16">16,18,19,27,43-53</a>]. The incidence of DVT for PICCs is between 5 and 15 percent for hospitalized patients and 2 to 5 percent for ambulatory patients [<a href="#rid44">44</a>]. Other systematic reviews have suggested that the risk of DVT associated with PICCs placed using modern techniques (eg, ultrasound-guided insertion, micropuncture needle) may be less; however, these reviews may be subject to study selection bias [<a href="#rid54">54,55</a>]. In a systematic review of 62 studies, PICCs were associated with a 2.5-fold greater risk of thromboembolism compared with CICCs [<a href="#rid16">16</a>]. (See  <a class="medical medical_review" href="/d/html/116371.html" rel="external">"Peripherally inserted central catheter (PICC)-related venous thrombosis in adults"</a>.)</p><p>Among CICCs, reported rates of thrombosis vary across sites of insertion, with higher rates reported for catheters placed in the femoral vessels compared with those placed in the internal jugular and subclavian veins [<a href="#rid42">42</a>]. (See  <a class="medical medical_review" href="/d/html/115957.html" rel="external">"Central venous access: Device and site selection in adults", section on 'Access site'</a>.)</p><p class="headingAnchor" id="H85798025"><span class="h4">Catheter malposition</span><span class="headingEndMark"> — </span>Following placement of central catheters, the position of the catheter tip has traditionally been confirmed with plain chest radiography. However, alternative approaches are accurate and cost effective. Proper catheter positioning is discussed elsewhere. (See  <a class="medical medical_review" href="/d/html/8194.html" rel="external">"Central venous access in adults: General principles", section on 'Confirming catheter tip position'</a>.)</p><p>Malposition of the tip of a central catheter may be associated with an increased risk of venous thrombosis. In one study, upper extremity DVT developed in 46 percent of patients whose catheter tip was in the brachiocephalic vein or at the junction of the brachiocephalic vein with the superior vena cava, compared with 6 percent of patients with a properly positioned catheter with its tip in the right atrium or superior vena cava [<a href="#rid13">13</a>].</p><p class="headingAnchor" id="H85798245"><span class="h4">Catheter infection</span><span class="headingEndMark"> — </span>Bacterial infection may originate from the patient's skin, with migration along the catheter to the vascular space from contaminated intravenous fluids or from hematogenous spread from a remote site [<a href="#rid56">56</a>]. Prior catheter infection may also be a risk factor for the development of catheter-related thrombosis [<a href="#rid57">57</a>]. In surgical patients, the bacteria isolated are often associated with the bacteria present at the site of surgery (eg, patients who undergo gastrointestinal surgery often have gastrointestinal flora isolated). (See  <a class="medical medical_review" href="/d/html/2131.html" rel="external">"Catheter-related septic thrombophlebitis"</a>.)</p><p>The use of sterile technique during insertion and timely removal of indwelling catheters are important practices to prevent catheter-related infection [<a href="#rid58">58</a>]. (See  <a class="medical medical_review" href="/d/html/15671.html" rel="external">"Routine care and maintenance of intravenous devices", section on 'Universal care strategies'</a>.) </p><p class="headingAnchor" id="H1123861692"><span class="h3">History of deep vein thrombosis</span><span class="headingEndMark"> — </span>Prior DVT also increases the risk for catheter-related upper extremity venous thrombosis (OR 2.03, 95% CI 1.05-3.92) [<a href="#rid27">27</a>]. In a risk model examining prediction of PICC-related DVT, a history of DVT was a strong and independent risk factor for catheter-related thrombosis [<a href="#rid59">59</a>].</p><p class="headingAnchor" id="H8"><span class="h3">Prothrombotic states</span><span class="headingEndMark"> — </span>The presence of a number of congenital or acquired systemic prothrombotic conditions may increase the risk for catheter-related upper extremity venous thrombosis [<a href="#rid3">3,60-66</a>]. </p><p>It is well documented that factor V Leiden and prothrombin gene mutation 20210 are risk factors for non-catheter-related upper extremity DVT. Studies have also assessed the risk of catheter-related upper extremity DVT in carriers of these common mutations [<a href="#rid67">67</a>]. One prospective study of 252 consecutive patients found a nearly threefold increased risk of developing catheter-related upper extremity DVT in carriers of factor V Leiden or prothrombin gene mutations [<a href="#rid68">68</a>]. In a meta-analysis of 10 studies including 1000 patients with malignancy, an association was confirmed for both mutations [<a href="#rid60">60</a>]. The estimated attributable risk of catheter-related upper extremity DVT was 13.1 percent for factor V Leiden and 4.5 percent for prothrombin gene mutation. The indications for screening patients for such a prothrombotic condition are reviewed in detail elsewhere. (See  <a class="medical medical_review" href="/d/html/1351.html" rel="external">"Clinical presentation and diagnosis of the nonpregnant adult with suspected deep vein thrombosis of the lower extremity"</a>.)</p><p>In a prospective case-control study of 260 patients, a higher incidence of upper extremity DVT occurred in patients with antibody-positive heparin-related thrombocytopenia (HIT) with a central catheter compared with those without a central catheter (9 versus 0 percent, respectively) [<a href="#rid69">69</a>]. All thrombotic sites corresponded to the side with the central venous catheter, strongly implicating an interaction between the underlying hypercoagulable state of HIT and the local injury caused by the catheter.</p><p>A higher incidence (up to 32 percent) of symptomatic catheter-related upper extremity DVT is found in patients with underlying malignancies [<a href="#rid1">1,28,70</a>]. In one prospective cohort study of over 3000 patients with a variety of solid malignancies and implanted ports, 3.8 percent developed a catheter-related thrombosis over 12 months [<a href="#rid28">28</a>]. In a study of ambulatory patients with malignancy in the National Health System, in the presence of a PICC, DVT occurred in 6.2 percent of patients [<a href="#rid71">71</a>]. Cephalic vein insertion, as opposed to subclavian or jugular vein, was identified as a risk factor (highlighting the importance of the catheter-to-vein ratio in thrombosis). Patients with malignant processes involving the right lung, lymph nodes, or other mediastinal structures may present with catheter thrombosis as a consequence of thoracic central vein compression and thrombosis. The management of patients with central venous obstruction and superior vena cava syndrome is discussed elsewhere. (See  <a class="medical medical_review" href="/d/html/1352.html" rel="external">"Risk and prevention of venous thromboembolism in adults with cancer"</a> and  <a class="medical medical_review" href="/d/html/1362.html" rel="external">"Overview of the treatment of proximal and distal lower extremity deep vein thrombosis (DVT)"</a> and  <a class="medical medical_review" href="/d/html/2832.html" rel="external">"Malignancy-related superior vena cava syndrome"</a>.)</p><p class="headingAnchor" id="H9"><span class="h3">Hormonal therapy</span><span class="headingEndMark"> — </span>An association between hormonal therapy and primary (ie, non-catheter-related) upper extremity DVT has been established. Observational studies of pregnant women who receive PICCs for a variety of indications suggest that these patients experience a high rate of thrombosis [<a href="#rid72">72,73</a>]. (See  <a class="medical medical_review" href="/d/html/1349.html" rel="external">"Deep vein thrombosis in pregnancy: Epidemiology, pathogenesis, and diagnosis"</a>.)</p><p>Whether hormonal therapy increases the risk of catheter-related thrombosis is unclear. Oral contraceptives may increase the risk for catheter-related upper extremity DVT when used in a patient with prothrombotic mutations, such as prothrombin 20210 or factor V Leiden [<a href="#rid67">67,74</a>]. Case reports of catheter-related upper extremity DVT (with or without coagulation abnormalities) are also reported in women undergoing ovulation induction and in vitro fertilization [<a href="#rid75">75-77</a>]. (See  <a class="medical medical_review" href="/d/html/7399.html" rel="external">"Combined estrogen-progestin contraception: Side effects and health concerns", section on 'Venous thromboembolism'</a>.) </p><p class="headingAnchor" id="H10"><span class="h3">Chemical irritation</span><span class="headingEndMark"> — </span>Chemical phlebitis can occur as a reaction to the catheter material or to the infused drugs contacting the venous intima. Common culprits include <a class="drug drug_general" data-topicid="9795" href="/d/drug information/9795.html" rel="external">potassium chloride</a>, <a class="drug drug_general" data-topicid="9345" href="/d/drug information/9345.html" rel="external">diazepam</a>, certain antibiotics (eg, <a class="drug drug_general" data-topicid="10037" href="/d/drug information/10037.html" rel="external">vancomycin</a> and <a class="drug drug_general" data-topicid="9724" href="/d/drug information/9724.html" rel="external">oxacillin</a>), chemotherapy agents, and hypotonic (&lt;250 mOsm/kg) or hypertonic (&gt;350 mOsm/kg) electrolyte solutions [<a href="#rid78">78</a>]. </p><p>The majority of these agents generally cause minor-to-moderate reactions that cease when the infusion is discontinued; however, chemotherapeutic agents can cause severe, persistent venous irritation. Some such agents also have irritant or vesicant properties and can cause necrosis of the subcutaneous tissues if leakage outside the vein occurs  (<a class="graphic graphic_table graphicRef67517" href="/d/graphic/67517.html" rel="external">table 1</a>). It is important to note that not all vesicant agents cause venous irritation during the injection. (See  <a class="medical medical_review" href="/d/html/2797.html" rel="external">"Extravasation injury from cytotoxic and other noncytotoxic vesicants in adults"</a>.)</p><p class="headingAnchor" id="H11"><span class="h1">CLINICAL PRESENTATION</span><span class="headingEndMark"> — </span>The symptoms and signs of venous thrombosis are related to local effects and to embolization, either to the pulmonary circulation or, paradoxically, to the systemic arterial bed.</p><p>Local effects are due to the inflammatory reaction incited by the thrombus causing primarily pain and tenderness along the course of the vein. These findings are more obvious when a superficial vein is affected. Obstruction of upper extremity flow may cause congestion of the collateral veins of the shoulder and chest wall on the affected side. The patient may or may not take notice of the venous patterning that results.</p><p>Thrombosis of the deep veins is often asymptomatic or can present with mild symptoms. A high index of suspicion is necessary to make the diagnosis, and some cases go unrecognized, especially in patients with a variety of other major medical problems. This may partially account for the wide variation in reported incidence of thrombosis, and it underscores the need for careful ongoing clinical assessment of patients with central venous catheters. (See  <a class="medical medical_review" href="/d/html/131420.html" rel="external">"Clinical features, diagnosis, and classification of thoracic central venous obstruction", section on 'Diagnosis'</a> and <a class="local">'Diagnostic evaluation'</a> below.)</p><p class="headingAnchor" id="H12"><span class="h2">No symptoms</span><span class="headingEndMark"> — </span>The reported incidence of asymptomatic catheter-related upper extremity deep vein thrombosis (DVT) in prospective series of patients with subclavian catheters has ranged from 5 to 13 percent [<a href="#rid13">13,79,80</a>]. However, thrombi are detected in over 50 percent of patients with malignancy and those undergoing bone marrow transplantation [<a href="#rid1">1,81</a>]. These thrombi range from nonocclusive mural thrombi to thrombi large enough to totally occlude the subclavian veins bilaterally. Why some individuals are asymptomatic, while others with thrombi in similar anatomic locations have debilitating symptoms, is largely unknown. </p><p>Inability to withdraw blood from or infuse into an indwelling catheter in an otherwise asymptomatic patient is a common occurrence, noted in 14 to 36 percent of patients within one to two years of central catheter placement [<a href="#rid82">82</a>]. The mechanism of the obstruction may be either thrombotic or mechanical (eg, kink in the catheter tubing, tight suture, catheter tip positioned against vessel wall, precipitation of infused drugs or lipid residues). Mechanical problems account for 40 percent of catheter occlusions, while thrombi account for the remainder.</p><p>Occluding thrombus usually does not originate in the lumen of the catheter but rather begins as a "fibrin sheath" encasing the catheter tip. The fibrin sheath represents a natural response of the vein wall to the catheter tip, with as many as 100 percent of catheters developing this phenomenon over time. Formation of the fibrin sheath can block the withdrawal of blood from the catheter by creating a one-way valve over the catheter tip, impairing the ability to withdraw blood from the catheter but allowing infusion through it, the so-called "ball-valve effect" or "withdrawal occlusion." Propagation of thrombus around the catheter can ultimately prevent both infusion and withdrawal from the catheter.</p><p class="headingAnchor" id="H14"><span class="h2">Symptomatic</span><span class="headingEndMark"> — </span>The clinical manifestations of catheter-related venous thrombosis are variable, and patients can be mildly symptomatic or have debilitating symptoms. Clinicians caring for patients with indwelling catheters must be vigilant in their attempts to identify and treat thrombotic catheter complications.</p><p class="headingAnchor" id="H15"><span class="h3">Phlebitis</span><span class="headingEndMark"> — </span>Phlebitis refers to an inflammatory reaction within the vein that gives rise to clinical findings of pain, tenderness, induration, and/or erythema along the course of that vessel. While phlebitis does not represent infection, it is usually difficult to differentiate from infection, and phlebitis predisposes to and often leads to infected lines/veins. </p><p>Phlebitis of a superficial veins with or without thrombosis is frequently associated with the use of peripheral intravenous catheters and is more common in patients who are immunocompromised (eg, burns, transplant) [<a href="#rid11">11</a>]. </p><p>Patients with central venous catheters, particularly peripherally inserted central catheters (PICCs), can also present with phlebitis of the superficial veins where those devices are inserted (eg, basilic vein, cephalic vein). PICCs can cause extensive superficial vein thrombosis and phlebitis due to the length of vein traversed by the catheter [<a href="#rid17">17</a>]. Phlebitis in superficial veins due to peripheral venous catheters is generally a benign, self-limited disorder once the catheter is removed. (See <a class="local">'Treatment'</a> below and  <a class="medical medical_review" href="/d/html/17036.html" rel="external">"Overview of thoracic central venous obstruction", section on 'Management'</a>.)</p><p>The phlebitic reaction in deeper veins leads to pain and tenderness overlying the insertion site of the catheter. Induration, erythema, or congestion of tributary veins may be appreciated at the base of the neck, infraclavicular fossa, shoulder, or arm depending upon the location and type of catheter. </p><p>The differential diagnosis of these symptoms in patients with underlying malignancy includes local tumor invasion, malignant lymphadenopathy, and bone metastasis, which may be complicated by pathologic fracture (especially of the clavicle).</p><p>Suppurative (infected) thrombophlebitis causes significant local symptoms, and the patient may be toxic with bacteremia or fungemia. Suppurative thrombophlebitis can be initiated by infection of catheter-associated thrombus. Purulent material may emanate from the catheter exit site in patients with peripheral intravenous catheters and tunneled catheters. The management of suppurative thrombophlebitis is discussed in detail elsewhere. (See  <a class="medical medical_review" href="/d/html/2131.html" rel="external">"Catheter-related septic thrombophlebitis"</a> and  <a class="medical medical_review" href="/d/html/3813.html" rel="external">"Intravascular non-hemodialysis catheter-related infection: Clinical manifestations and diagnosis"</a> and  <a class="medical medical_review" href="/d/html/3814.html" rel="external">"Intravascular non-hemodialysis catheter-related infection: Treatment"</a>.)</p><p class="headingAnchor" id="H16"><span class="h3">Extremity edema</span><span class="headingEndMark"> — </span>Obstruction of the major thoracic veins can cause edema (usually unilateral) of the arm and hand, depending upon the extent of collateral venous flow from the upper extremity. Swelling is often exercise dependent or may appear if the arm is kept dependent for prolonged periods or when the arm is used vigorously. In some patients, the edema is a subjective symptom, described as a feeling of fullness in the fingers with rings feeling "too tight." The differential diagnosis of arm swelling is broad and includes lymphedema, muscle injury, intracompartmental hematomas, or thoracic outlet obstruction. Therefore, signs and symptoms of edema are not reliable for the diagnosis of thrombosis because of the poor specificity of clinical findings. (See  <a class="medical medical_review" href="/d/html/17036.html" rel="external">"Overview of thoracic central venous obstruction", section on 'Clinical presentations'</a>.)</p><p>If bilateral upper extremity DVT is suspected in a patient with bilateral upper extremity edema, it can be distinguished from more generalized fluid retention by the absence of lower extremity edema. (See  <a class="medical medical_review" href="/d/html/6878.html" rel="external">"Clinical manifestations and evaluation of edema in adults"</a>.)</p><p class="headingAnchor" id="H17"><span class="h3">Embolization</span><span class="headingEndMark"> — </span>A high index of suspicion for occult subclavian vein thrombosis is necessary when evaluating a susceptible patient with symptoms suggestive of pulmonary emboli or acute neurologic insult. Symptoms consistent with embolization in an otherwise asymptomatic patient with a central catheter may provide the first clues to the presence of upper extremity DVT. This possibility is often overlooked clinically. Although low, the risk of embolization is not negligible and more likely associated with thrombosis in the deep compared with the superficial upper extremity veins [<a href="#rid4">4</a>]. Fatal pulmonary embolism has been reported, even in patients treated with anticoagulants [<a href="#rid83">83</a>]. (See  <a class="medical medical_review" href="/d/html/8261.html" rel="external">"Clinical presentation, evaluation, and diagnosis of the nonpregnant adult with suspected acute pulmonary embolism"</a>.)</p><p>The incidence of pulmonary embolus is relatively low for both catheter-related and spontaneous upper extremity DVT [<a href="#rid5">5</a>]. In patients with upper extremity DVT, one United States registry (324 patients) and one European Registry (11,564 patients) reported rates of symptomatic pulmonary embolus of 1 and 8 percent, respectively [<a href="#rid5">5,6</a>]. The incidence is higher in patients with malignancy. A higher incidence of 36 percent was reported in one study but may reflect the higher incidence of patients with thrombotic disorders and malignancy [<a href="#rid84">84</a>]. In the GARFIELD-VTE registry, rates of recurrence of thromboembolism did not differ in patients who developed upper versus lower extremity DVT (4 versus 5.5 per 100 person-years, respectively) [<a href="#rid14">14</a>].</p><p class="headingAnchor" id="H18"><span class="h2">Clinical prediction score</span><span class="headingEndMark"> — </span>A clinical score for predicting the presence of upper extremity DVT was developed in a derivation cohort of 140 patients and confirmed in two separate validation cohorts with a total of 217 additional patients. All episodes were objectively confirmed by ultrasound examination. A risk score was generated from the following four parameters [<a href="#rid85">85</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Presence of a catheter or access device in a subclavian or jugular vein or a pacemaker (plus 1 point)</p><p class="bulletIndent1"><span class="glyph">●</span>Unilateral pitting edema (plus 1 point)</p><p class="bulletIndent1"><span class="glyph">●</span>Presence of localized pain in that extremity (plus 1 point)</p><p class="bulletIndent1"><span class="glyph">●</span>Another diagnosis at least as plausible (minus 1 point)</p><p></p><p>Total scores were then rated as low probability (zero points or less, prevalence of upper extremity DVT 9 to 13 percent), intermediate probability (one point, prevalence 20 to 38 percent), or high probability (2 to 3 points, prevalence 64 to 70 percent). </p><p>A PICC-specific score is also used and presented separately. (See  <a class="medical medical_review" href="/d/html/116371.html" rel="external">"Peripherally inserted central catheter (PICC)-related venous thrombosis in adults", section on 'Risk prediction'</a>.)</p><p class="headingAnchor" id="H19"><span class="h1">DIAGNOSTIC EVALUATION</span><span class="headingEndMark"> — </span>The methods to diagnose catheter-related upper extremity deep vein thrombosis (DVT) are similar to those of the primary upper extremity DVT (ie, Paget-Schroetter syndrome). However, a greater emphasis should be placed on noninvasive methods, usually beginning with duplex ultrasound and, possibly, D-dimer testing (a fibrin degradation product) [<a href="#rid86">86</a>]. (See  <a class="medical medical_review" href="/d/html/8211.html" rel="external">"Primary (spontaneous) upper extremity deep vein thrombosis", section on 'Diagnosis'</a> and  <a class="medical medical_review" href="/d/html/8211.html" rel="external">"Primary (spontaneous) upper extremity deep vein thrombosis", section on 'D-dimer'</a>.)</p><p>At least two studies have evaluated the role of D-dimer in patients with suspected upper extremity DVT [<a href="#rid87">87,88</a>]. Both studies found that in patients with image-confirmed thrombosis, D-dimer had high sensitivity but suffered from poor specificity. Therefore, a strategy using D-dimer to rule in or rule out upper extremity DVT cannot be recommended. </p><p class="headingAnchor" id="H3489880880"><span class="h2">Sequential prediction rule</span><span class="headingEndMark"> — </span>A sequential approach incorporating risk stratification and biomarkers may prove useful when approaching upper extremity thrombosis. Extrapolating from the approach in lower extremity DVT, investigators in the ARMOUR study examined whether an algorithm beginning with risk stratification using the rule by Constans, followed by D-dimer testing and compression ultrasonography, could better rule in/rule out patients with upper extremity DVT [<a href="#rid86">86</a>]. Evaluation of the rule in a cohort of patients at varying risk of upper extremity thrombosis revealed that the tool performed well in identifying patients at low risk of events. Approximately one-fifth of patients in the cohort of 406 patients avoided ultrasound imaging through use of this approach. However, application of the approach in another study consisting of a higher-risk cohort (patients older than 75, hospitalized patients, those with malignancy, or those with upper extremity catheters/devices) showed that the ability to distinguish a subset of patients where imaging could be withheld in this setting was low [<a href="#rid89">89</a>]. Thus, this approach might be more useful in patients deemed to be at low risk of venous thromboembolism. </p><p class="headingAnchor" id="H4101502502"><span class="h2">Vascular imaging</span></p><p class="headingAnchor" id="H20"><span class="h3">Duplex ultrasonography</span><span class="headingEndMark"> — </span>Ultrasound examination is the screening tool of choice to evaluate for upper extremity venous thrombosis because it is noninvasive, has no ionizing radiation or contrast-dye exposure, and is relatively easy to perform [<a href="#rid90">90,91</a>]. Similar to the lower extremities, a completely normal finding on ultrasonography of the upper extremity can safely exclude DVT [<a href="#rid90">90</a>]. Noncompressibility of the vein, abnormal flow (eg, flow reversal), and visible intraluminal thrombus are the major criteria for the diagnosis of thrombosis. Sensitivity and specificity range from 80 to 100 percent [<a href="#rid84">84,92</a>]. The chance of a false-positive study is very low; however, nonocclusive mural thrombus and thrombus in the proximal subclavian or brachiocephalic veins (generally shadowed by the clavicle and sternum) may not be adequately visualized. Additional imaging using computed tomographic venography or magnetic resonance (MR) imaging venography may be needed if the clinical suspicion for thrombosis is high. </p><p>When asymptomatic upper extremity DVT is suspected, the same techniques effective in the diagnosis of symptomatic thrombi are used. However, duplex ultrasound has a lower sensitivity in this setting, making a negative study noncontributory to patient care. </p><p>Patients with asymptomatic or nonocclusive deep vein thrombus or superficial vein thrombus of veins approaching the deep venous system (eg, basilic vein, cephalic vein) who do not respond to removal of the catheter and other conservative measures, or have progression of their symptoms, should undergo repeat duplex examination to evaluate for progression or extension of clot. Advanced imaging techniques may also be considered in these situations. </p><p class="headingAnchor" id="H2006310286"><span class="h3">MR venography</span><span class="headingEndMark"> — </span>Because MR imaging avoids radiation exposure and can provide detailed imaging of the veins, some studies have evaluated the role of MR venography to detect upper extremity DVT. In one small study of 18 patients, this technique had a sensitivity of 71 percent and a specificity of 89 percent for imaging without contrast. A pilot study of three patients with DVT identified on ultrasound similarly confirmed thrombosis in all vein segments, suggesting that the approach may be feasible [<a href="#rid93">93</a>]. However, because of the cost of this technique and limited evidence of effectiveness, its use cannot be widely recommended at this time [<a href="#rid94">94</a>]. </p><p class="headingAnchor" id="H21"><span class="h3">Catheter-based contrast venography</span><span class="headingEndMark"> — </span>Venography may be indicated if clinical suspicion for upper extremity DVT is high and the ultrasound is negative or nondiagnostic. For mechanical catheter problems, instillation of intravenous contrast into the lumen of the catheter under fluoroscopy may readily demonstrate the presence of thrombus at the tip of the catheter.</p><p>Digital subtraction venography can be performed if an aggressive diagnostic approach is required. Venography requires cannulation of either a peripheral vein or a central vein (eg, subclavian, femoral). Because poor venous patency is one of the reasons that indwelling catheters are needed in the first place, access for venography can be challenging.</p><p class="headingAnchor" id="H22"><span class="h1">TREATMENT</span><span class="headingEndMark"> — </span>The goals in managing catheter-related upper extremity venous thrombosis include alleviation of symptoms, minimizing the risk for embolization, and providing for continued intravenous access, if it is needed.</p><p class="headingAnchor" id="H23"><span class="h2">Superficial vein thrombosis and phlebitis</span><span class="headingEndMark"> — </span>There are limited data to guide management of upper extremity superficial vein thrombosis and phlebitis of upper extremity veins. Fortunately, it appears that pulmonary embolus from superficial vein thrombosis and phlebitis is very rare. </p><p class="headingAnchor" id="H68320828"><span class="h3">Initial symptomatic care</span><span class="headingEndMark"> — </span>The initial management of superficial vein thrombosis and phlebitis related to peripheral intravenous catheters consists of discontinuing the intravenous infusion and removing the peripheral catheter. </p><p>Symptomatic care includes extremity elevation, warm or cool compresses, and oral nonsteroidal anti-inflammatory agents (NSAIDs). Topical NSAIDs may also be effective in relieving local burning associated with phlebitis.</p><p>When managing phlebitis, the catheter insertion site should be closely monitored. Excessive pain may indicate suppurative phlebitis, chemical phlebitis, or extravasation of infused fluid into the subcutaneous tissues. Additional treatment, including surgery, may be required to manage extravasation injuries. Antibiotics should be initiated if there is any concern for suppurative thrombophlebitis. (See  <a class="medical medical_review" href="/d/html/2131.html" rel="external">"Catheter-related septic thrombophlebitis"</a> and  <a class="medical medical_review" href="/d/html/2797.html" rel="external">"Extravasation injury from cytotoxic and other noncytotoxic vesicants in adults"</a>.)</p><p class="headingAnchor" id="H125444785"><span class="h3">Role of anticoagulation</span><span class="headingEndMark"> — </span>Extrapolating data regarding the role of anticoagulation from the lower extremity, it would be reasonable to also consider anticoagulation for patients with upper extremity superficial vein thrombosis who are at risk for DVT (eg, superficial vein thrombosis in proximity to the deep veins, thrombophilia) [<a href="#rid4">4,95-97</a>]. For spontaneous lower extremity superficial vein thrombosis, patients who are not anticoagulated have a higher incidence of persistent pain and thrombus recurrence/extension [<a href="#rid98">98</a>]. Based upon reviews of randomized trials, anticoagulation is suggested in patients with lower extremity superficial vein thrombosis who are at risk for deep vein thrombosis (DVT). As an example, in one systematic review and meta-analysis involving 6862 patients, anticoagulation with <a class="drug drug_general" data-topicid="8691" href="/d/drug information/8691.html" rel="external">fondaparinux</a> (a synthetic anticoagulant, factor Xa inhibitor) in patients with lower extremity superficial vein thrombosis was associated with reduced rates of subsequent thromboembolism [<a href="#rid99">99</a>]. Providing anticoagulation may be more important for patients with underlying malignancy in whom a predisposition to thrombosis is known to exist. (See  <a class="medical medical_review" href="/d/html/8199.html" rel="external">"Superficial vein thrombosis and phlebitis of the lower extremity veins", section on 'Treatment of SVT'</a>.)</p><p>Patients with basilic or cephalic vein thrombosis who remain symptomatic (eg, edema, pain) despite catheter removal may also be considered for anticoagulation treatment to manage symptoms. As with superficial vein thrombosis and phlebitis of the lower extremity, anticoagulation in these patients may be effective in alleviating symptoms, especially in the setting of malignancy. Whether anticoagulation improves the future patency of the superficial veins has not been adequately investigated. The duration of therapy under these circumstances needs to be guided by clinical judgment. Ultrasound can be repeated if symptoms progress to rule out extension into the deep venous system. (See <a class="local">'Duplex ultrasonography'</a> above.)</p><p class="headingAnchor" id="H25"><span class="h2">Deep vein thrombosis</span><span class="headingEndMark"> — </span>For patients with upper extremity DVT, embolism is less common compared with lower extremity DVT due to differences in epidemiology and risk factors [<a href="#rid14">14</a>]. (See <a class="local">'Epidemiology and risk factors'</a> above.)</p><p>Nevertheless, venous thromboembolism is still a serious problem. Thus, therapy for upper extremity catheter-related DVT is also directed toward preventing this complication. Anticoagulant therapy is generally effective for preventing pulmonary embolism in patients with lower extremity DVT. By inference, anticoagulation should also be effective for preventing embolization from thrombosed thoracic veins, although treatment failures occur at both locations [<a href="#rid83">83,95-97</a>]. However, no treatment scheme has been rigorously evaluated for its efficacy in preventing embolization from upper extremity sources. As a result, recommendations for the treatment of upper extremity DVT are based largely upon indirect evidence from the experience with DVT of the lower extremities. (See  <a class="medical medical_review" href="/d/html/1362.html" rel="external">"Overview of the treatment of proximal and distal lower extremity deep vein thrombosis (DVT)"</a>.)</p><p>Patients with catheter-related thrombosis become rapidly asymptomatic with various combinations of observation, anticoagulation, and removal of the thrombogenic stimulus (the catheter). Individual case reports suggest that some patients with catheter-related thrombosis have symptoms that do not resolve; however, these patients appear to be in the minority.</p><p>Catheter-related upper extremity DVT is generally managed more conservatively compared with primary (spontaneous) upper extremity DVT. The more aggressive approach used with spontaneous thrombosis is due to a higher incidence of postphlebitic sequelae. In a systematic review, the incidence of post-thrombotic syndrome (PTS) ranged from 7 to 46 percent following upper extremity DVT in adults [<a href="#rid100">100</a>]. Residual thrombosis and axillosubclavian vein thrombosis were associated with PTS, but catheter-associated upper extremity DVT was associated with reduced risk. (See  <a class="medical medical_review" href="/d/html/8211.html" rel="external">"Primary (spontaneous) upper extremity deep vein thrombosis"</a>.)</p><p class="headingAnchor" id="H26"><span class="h3">Anticoagulation</span><span class="headingEndMark"> — </span>Despite a lack of direct evidence proving safety and efficacy of anticoagulation for upper extremity DVT, anticoagulant therapy remains the cornerstone of therapy with a goal of relieving acute symptoms and preventing embolization [<a href="#rid96">96,101-103</a>]. In patients with acute upper extremity DVT involving the axillary or more proximal veins, we recommend anticoagulation, as described for lower extremity DVT, provided there are no contraindications, with or without catheter removal. For isolated brachial vein thrombosis, the intensity and duration of anticoagulation is uncertain, and decision-making should be individualized. This recommendation is consistent with guidelines from the American College of Chest Physicians (ACCP) and other international guidelines [<a href="#rid96">96,97,104</a>]. (See  <a class="medical medical_review" href="/d/html/1362.html" rel="external">"Overview of the treatment of proximal and distal lower extremity deep vein thrombosis (DVT)", section on 'Patients at low risk of bleeding'</a>.)</p><p>The type and intensity of anticoagulant therapy with catheter-related DVT should be similar to that given to prevent embolization of thrombi from the deep veins of the legs. We suggest initial therapy with parenteral anticoagulants (low-molecular-weight heparin [LMWH], <a class="drug drug_general" data-topicid="8691" href="/d/drug information/8691.html" rel="external">fondaparinux</a>, <a class="drug drug_general" data-topicid="8518" href="/d/drug information/8518.html" rel="external">unfractionated heparin</a>) followed by LMWH or a vitamin K antagonist (eg, <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a>). Sufficient data are lacking to recommend the use of a direct oral anticoagulant (DOAC) for the management of the acute phase of catheter-related upper extremity DVT. However, observational and small controlled studies examining the utility of DOACs in upper extremity thrombosis are emerging [<a href="#rid105">105,106</a>]. Therapeutic options for DVT are discussed in detail elsewhere. (See  <a class="medical medical_review" href="/d/html/1362.html" rel="external">"Overview of the treatment of proximal and distal lower extremity deep vein thrombosis (DVT)"</a>.)</p><p>In general, we manage catheter-related upper extremity deep vein thrombosis in the following manner:</p><p class="bulletIndent1"><span class="glyph">●</span>For patients who have an ongoing need for the catheter, it is reasonable to administer anticoagulant therapy without catheter removal, provided the device remains functional and its tip is well positioned (see <a class="local">'Catheter management'</a> below) [<a href="#rid7">7,97</a>]. This approach has been associated with good clinical outcomes in small series of patients, including patients with malignancy [<a href="#rid107">107-109</a>]. The optimal duration of anticoagulation when the catheter stays in place has not been defined. The ACCP guidelines recommend continuing anticoagulation provided the central venous catheter remains in place, especially in patients with malignancy. If the catheter needs to be removed, no data are available to indicate whether central venous catheter removal should be preceded by a brief period of anticoagulation to minimize risk of embolization. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>There is uncertainty about the need to anticoagulate patients with thrombosis confined to the brachial vein [<a href="#rid97">97</a>]. The risk of long-term chronic venous sequelae from venous obstruction at this site generally appears to be quite small. The ACCP guidelines favor anticoagulation for up to three months if the thrombosis is symptomatic, is associated with malignancy, or the catheter remains in place [<a href="#rid97">97</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The optimal strategy for patients with upper extremity DVT who have contraindications to systemic anticoagulation is unknown. In most cases, removal of the catheter is recommended to prevent clot propagation and speed resolution of thrombosis. Localized procedures such as thrombectomy or catheter-directed therapies may be performed in instances of massive thrombosis but must be considered on a case-by-case basis. (See <a class="local">'Deep vein thrombolysis'</a> below and  <a class="medical medical_review" href="/d/html/17036.html" rel="external">"Overview of thoracic central venous obstruction", section on 'Endovenous intervention'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Whether asymptomatic upper extremity DVT should be treated is more controversial and less well defined than treatment of symptomatic thrombosis. While asymptomatic thrombosis in the lower extremity is well recognized as a source of embolization, the rate of this or other complications with asymptomatic thoracic central vein thrombosis is not known [<a href="#rid84">84</a>]. Consequently, the risk/benefit analysis of any potential treatment cannot be determined. However, there is no theoretical reason to believe that the risk of embolization is any different compared with symptomatic thoracic central vein thrombi, unless chronic in nature. In addition, asymptomatic upper extremity DVT can cause permanent obstruction in the subclavian vein and may interfere with subsequent catheter placement, resulting in loss of central venous access on the affected side. As an example of this last point, one series noted that 14 percent of patients undergoing a second or third catheter placement failed the procedure because of obstruction.</p><p></p><p class="headingAnchor" id="H28"><span class="h3">Deep vein thrombolysis</span><span class="headingEndMark"> — </span>Most patients with catheter-related upper extremity DVT do <strong>not</strong> need catheter-directed thrombolytic therapy. Although some authors have advocated its use, there is no hard evidence that better outcomes are achieved compared with conservative therapy with anticoagulation. These interventions are time-consuming, expensive, and not without morbidity. Since thrombolytic therapy is indicated to minimize long-term symptoms, the impact of this potential problem on the patient's quality of life should first be determined.</p><p>Catheter-directed thrombolytic therapy would seem logical for individuals with significant symptoms in the acute stages of thrombosis (symptoms less than 14 days) who have met all of the following criteria (see  <a class="medical medical_review" href="/d/html/120732.html" rel="external">"Endovenous intervention for thoracic central venous obstruction"</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>Have not adequately responded to systematic anticoagulation </p><p class="bulletIndent1"><span class="glyph">●</span>Have a low risk for bleeding </p><p class="bulletIndent1"><span class="glyph">●</span>Have a good long-term prognosis relative to their underlying disease </p><p class="bulletIndent1"><span class="glyph">●</span>Have a lifestyle that requires vigorous use of the affected arm </p><p></p><p>Patients who do not meet these criteria (eg, a patient with limited life expectancy from their coexistent medical problems who does not require extensive use of their arm) are likely to do just as well with conservative therapy.</p><p class="headingAnchor" id="H29"><span class="h2">Catheter management</span></p><p class="headingAnchor" id="H30"><span class="h3">Functioning</span><span class="headingEndMark"> — </span>Maintenance of the catheter in a thrombosed vein is justified if it is mandatory, functional, in the correct position, and not infected. Anticoagulation is instituted and clinical symptoms monitored closely for signs of improvement for as long as the catheter is present [<a href="#rid101">101</a>]. Worsening of symptoms while anticoagulated indicates a need to remove the line and repeat the duplex examination.</p><p class="headingAnchor" id="H31"><span class="h3">Occluded</span><span class="headingEndMark"> — </span>Occluded catheters often need to be removed and replaced. However, many patients have limited access sites. Replacement of the catheter risks recurrent endothelial injury and recurrence of thrombosis at the new catheter site. Thus, salvage of a catheter that has a thrombotic (ie, not mechanical) occlusion can be attempted with the instillation of fibrinolytic agents [<a href="#rid110">110</a>]. </p><p>The decision to use thrombolytic therapy (eg, tissue plasminogen activator [tPA]) for upper extremity catheter thrombosis that is refractory to usual initial measures (ie, normal <a class="drug drug_general" data-topicid="9929" href="/d/drug information/9929.html" rel="external">saline</a> flush, repositioning) is mainly clinical, considering the available resources (drug availability, interventional radiology expertise) and the degree of need for rapid restoration of catheter function. For thrombotic occlusions unresponsive to two or more attempts using the thrombolytic agent, objective evaluation with radiologic techniques is advisable since some instances may be due to mechanical problems (eg, fibrin sheath or tip malposition) amenable only to mechanical solutions. (See <a class="local">'Catheter-based contrast venography'</a> above and  <a class="medical medical_review" href="/d/html/131420.html" rel="external">"Clinical features, diagnosis, and classification of thoracic central venous obstruction", section on 'Diagnosis'</a>.) </p><p>Thrombolytic agents that have predominantly been studied for this indication include t-PA or <a class="drug drug_general" data-topicid="8478" href="/d/drug information/8478.html" rel="external">alteplase</a>, and urokinase [<a href="#rid110">110-120</a>]. In the United States and elsewhere, alteplase (Cathflo, Activase) is more commonly used to manage catheter occlusion. Alteplase is available in 2 mg vials for use in this setting. For adults weighing ≥30 kg, one or two doses of 2 mg (1 mg/mL) of alteplase (t-PA) with a recommended dwell time of 30 to 120 minutes per dose are generally successful in restoring catheter function [<a href="#rid121">121,122</a>]. Lower-weight patients (&lt;30 kg) should receive a reduced dose adjusted to catheter lumen volume. The efficacy and safety of local instillation of alteplase was confirmed with catheter function restored in 74 and 90 percent after one or two doses, respectively [<a href="#rid119">119,121</a>]. The approach using thrombolytics to restore hemodialysis catheter function and its effectiveness are reviewed separately. (See  <a class="medical medical_review" href="/d/html/1906.html" rel="external">"Malfunction of chronic hemodialysis catheters", section on 'Treatment approach for intrinsic thrombus'</a>.)</p><p>Urokinase is not available in the United States and has been found to be less effective compared with <a class="drug drug_general" data-topicid="8478" href="/d/drug information/8478.html" rel="external">alteplase</a> in small randomized trials [<a href="#rid113">113,118,123</a>]. Outside of the United States, urokinase may still be in use [<a href="#rid124">124</a>]. Guidance on urokinase dosage for the management of dysfunctional central venous catheters has been published for use in the United Kingdom with suggested doses of urokinase (Syner-Kinase) 10,000 international units for each lumen using a PushLock technique or dwell time of 30 to 60 minutes [<a href="#rid124">124</a>]. For persistent withdrawal occlusion or for hemodialysis catheters, a higher dose of urokinase (25,000 international units per lumen) is recommended. The value of intraluminal lytic enzyme infusion is unknown. </p><p class="headingAnchor" id="H32"><span class="h1">THROMBOSIS PREVENTION</span><span class="headingEndMark"> — </span>Routine prophylactic systemic anticoagulation is <strong>not</strong> recommended for patients with indwelling central venous catheters [<a href="#rid97">97,101,104,125-127</a>]. Although randomized trials have not definitively demonstrated a clinically significant benefit for prophylactic anticoagulation in patients with malignancy, a decision for prophylactic anticoagulation may be reasonable if the clinical evaluation suggests the risks associated with thrombosis outweigh the risks of bleeding, taking into account tumor location and any prior history of thrombosis or bleeding [<a href="#rid127">127-129</a>]. It may be possible to identify high-risk patients who will benefit from prophylactic anticoagulation based upon specific factors (eg, chemotherapy) [<a href="#rid27">27</a>]. (See <a class="local">'Prophylactic anticoagulation'</a> below.)</p><p class="headingAnchor" id="H14855013"><span class="h2">Site and catheter management</span><span class="headingEndMark"> — </span>Catheter-related thrombosis may be reduced using antithrombotic catheter lock solutions (eg, heparin, citrate). When thrombosis occurs, thrombolytic therapy may restore lumen patency, but thrombosis related to mechanical problems usually requires replacement of the catheter. (See <a class="local">'Catheter management'</a> above.) </p><p class="headingAnchor" id="H692376821"><span class="h2">Prophylactic anticoagulation</span><span class="headingEndMark"> — </span>Most randomized trials in adults evaluating prophylactic anticoagulation with low-dose <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a>, <a class="drug drug_general" data-topicid="8518" href="/d/drug information/8518.html" rel="external">unfractionated heparin</a> (UFH), or low-molecular-weight heparin (LMWH) have been performed in adults with malignancy [<a href="#rid79">79,101,126,130-144</a>]. These subsets of patients have a high risk for venous thrombosis, yet a definitive clinical benefit for prophylactic anticoagulation in preventing catheter-related venous thrombosis has yet to be proven. </p><p>Early systematic reviews did not show any definitive benefit [<a href="#rid136">136,137,139-142,145</a>]; however, later meta-analyses that included a subsequent large trial found a decreased risk of symptomatic deep vein thrombosis (DVT) with prophylactic heparin and a decreased risk of asymptomatic DVT with low-dose <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a>, each compared with no anticoagulation [<a href="#rid143">143-146</a>]. The effects regarding vitamin K antagonists (VKAs) were uncertain, and comparison of prophylactic anticoagulation on mortality and adverse outcomes remains unclear in this study and in other reviews. The data have been inconsistent, likely due to differences in chosen endpoints, malignancy type, screening modality, and improvements in catheter-related factors over time [<a href="#rid137">137,139-142,145,147</a>]. Given this uncertainty, we continue to agree with various society guidelines that do <strong>not</strong> recommend routine prophylactic anticoagulation for the sole purpose of preventing catheter-related thrombosis [<a href="#rid104">104,126,127</a>]. However, in patients with malignancy, guidelines have endorsed pharmacologic prophylaxis of hospitalized patients at high risk of venous thromboembolism (eg, Khorana score of 2 or higher). The direct oral anticoagulants <a class="drug drug_general" data-topicid="9498" href="/d/drug information/9498.html" rel="external">rivaroxaban</a> and <a class="drug drug_general" data-topicid="99275" href="/d/drug information/99275.html" rel="external">edoxaban</a> have been added to recommendations as appropriate agents for thromboprophylaxis in hospitalized patients with malignancy, including those with central venous catheters [<a href="#rid129">129</a>]. While routine thromboprophylaxis is not recommended for outpatients with malignancy, a placebo-controlled trial of ambulatory patients with malignancy who were about to begin chemotherapy reported that prophylactic treatment with <a class="drug drug_general" data-topicid="85642" href="/d/drug information/85642.html" rel="external">apixaban</a> compared with placebo was associated with a significant reduction in DVT but with increased rates of bleeding [<a href="#rid148">148</a>]. (See  <a class="medical medical_review" href="/d/html/1352.html" rel="external">"Risk and prevention of venous thromboembolism in adults with cancer"</a>.)</p><p>Prophylactic systemic anticoagulation (heparin) may have a role in some high-risk patients when the perceived risk of thrombosis outweighs the risk of bleeding and the burden of anticoagulation. High-risk factors include hospitalization for malignancy, previous venous thrombosis, bulky disease, or hereditary thrombophilia [<a href="#rid27">27,128</a>]. Research efforts should focus on identifying patients most likely to benefit from prophylactic anticoagulation.</p><p class="bulletIndent1"><span class="glyph">●</span>A large trial randomly assigned 420 high-risk ambulatory patients about to undergo chemotherapy for malignancy to no anticoagulation, LMWH, or <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a> (1 mg/day) for three months [<a href="#rid146">146</a>]. Compared with no anticoagulation, prophylactic anticoagulation significantly reduced the incidence of catheter-related DVT (LMWH: 8 versus 20 events; warfarin: 14 versus 20 events), and catheter-nonrelated DVT (LMWH: 1 versus 7 events; warfarin: 1 versus 7 events), with no difference between warfarin and LMWH. A later meta-analysis that included trials similar to those in an earlier review as well as the large trial found a significant benefit for prophylactic anticoagulation (heparin, warfarin) over no anticoagulation for symptomatic DVT (risk ratio [RR] 0.61, 95% CI 0.42-0.88) [<a href="#rid144">144</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>An updated Cochrane review identified 13 randomized trials that evaluated the efficacy and safety of LMWH or VKAs for prevention of catheter-related venous thrombosis in patients with malignancy [<a href="#rid143">143,147</a>]. Among six adult trials, the incidence of symptomatic catheter-related thrombosis at three months was lower for LMWH compared to without (RR 0.43, 95% CI 0.22-0.81); VKA did not alter the risk for symptomatic catheter-related thrombosis. There were also no significant differences in bleeding, infection, or mortality for either LMWH or VKAs compared with no treatment. </p><p></p><p class="headingAnchor" id="H13360722"><span class="h2">Heparin-bonded catheters</span><span class="headingEndMark"> — </span>A number of central venous catheters are available that have heparin-bonded coatings designed to reduce catheter-associated thrombosis. To date, technology has not been able to produce heparin bonding that is sufficiently sustainable for use in longer-term catheters. (See  <a class="medical medical_review" href="/d/html/115957.html" rel="external">"Central venous access: Device and site selection in adults", section on 'Coated and impregnated catheters'</a>.)</p><p class="headingAnchor" id="H1818846133"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/113663.html" rel="external">"Society guideline links: Superficial vein thrombosis, deep vein thrombosis, and pulmonary embolism"</a> and  <a class="medical medical_society_guidelines" href="/d/html/117743.html" rel="external">"Society guideline links: Venous access"</a>.)</p><p class="headingAnchor" id="H463384350"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.) </p><p class="bulletIndent1"><span class="glyph">●</span>Basics topic (see  <a class="medical medical_basics" href="/d/html/87580.html" rel="external">"Patient education: Superficial vein phlebitis and thrombosis (The Basics)"</a>)</p><p></p><p class="headingAnchor" id="H37"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Catheter-related thrombosis</strong> – Intravenous catheters cause endothelial trauma and vein wall inflammation, which can result in thrombosis. Superficial vein thrombosis and phlebitis is most often related to peripheral intravenous catheters. Deep vein thrombosis can also occur and may lead to complications such as pulmonary embolism or post-thrombotic syndrome of the upper extremity. The majority of upper extremity deep vein thrombosis (DVT) events are due to peripherally inserted central catheters (PICCs). (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Risk factors</strong> – Risk factors for upper extremity catheter-related venous thrombosis include catheter-related factors (eg, catheter malposition, catheter size), the presence of prothrombotic states (congenital or acquired), hormonal therapy, and infusion of vesicant or irritant medications. (See <a class="local">'Epidemiology and risk factors'</a> above.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical features</strong> – The majority of symptoms and signs of catheter-related thrombosis are related to local effects of the thrombus (ie, phlebitis, venous obstruction [edema, pain]). Although less common, symptoms and signs arising from embolization to the pulmonary circulation, or paradoxically to the systemic circulation via a patent foramen ovale (eg, brain, periphery), can also occur. A high index of suspicion for thrombosis is needed when evaluating susceptible patients with catheters who have symptoms suggestive of pulmonary emboli or acute neurologic insult. (See <a class="local">'Clinical presentation'</a> above.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis</strong> – Duplex ultrasound is the initial imaging test of choice when upper extremity catheter-related venous thrombosis is suspected in asymptomatic and symptomatic patients. Patients who have had prior DVT should be screened for patency of the thoracic central veins prior to placement of a subsequent catheter. (See <a class="local">'Diagnostic evaluation'</a> above.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Superficial phlebitis</strong> – Superficial phlebitis related to peripheral intravenous catheters should be managed first by discontinuing the intravenous infusion and removing the peripheral catheter. Symptomatic care consists of extremity elevation, warm or cool compresses, and oral nonsteroidal anti-inflammatory drugs (NSAIDs). Excessive pain not controlled with NSAIDs may indicate the presence of a suppurative phlebitis, chemical phlebitis, or extravasation injury. (See <a class="local">'Phlebitis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Upper extremity deep vein thrombosis</strong> – For patients diagnosed with upper extremity catheter-related DVT, we suggest anticoagulation (<a class="grade" href="https://medilib.ir/uptodate/show/grade_5" rel="external">Grade 2B</a>). For uncomplicated cases, three months of anticoagulation therapy should be sufficient. A longer duration of anticoagulation may be warranted if the catheter remains in place, particularly for patients with malignancy. (See <a class="local">'Treatment'</a> above and  <a class="medical medical_review" href="/d/html/17036.html" rel="external">"Overview of thoracic central venous obstruction", section on 'Management'</a>.) </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For most patients with upper extremity catheter-related DVT, we suggest not instituting deep vein thrombolysis as a first-line therapy (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). Compared with anticoagulation, there is insufficient evidence to suggest that thrombolysis leads to any better outcomes. (See <a class="local">'Deep vein thrombolysis'</a> above and  <a class="medical medical_review" href="/d/html/17036.html" rel="external">"Overview of thoracic central venous obstruction", section on 'Endovenous intervention'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The catheter can be left in place if it is functional, has a well-positioned tip, and there is an ongoing clinical indication for its use. For patients without malignancy with thrombosis confined to the brachial vein, there is uncertainty about the need for anticoagulation once the catheter has been removed. (See <a class="local">'Catheter management'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prophylaxis against catheter-related thrombosis</strong> – For most patients with indwelling upper extremity catheters, we recommend <strong>not</strong> administering prophylactic anticoagulation (vitamin K antagonists, low-molecular-weight heparin, <a class="drug drug_general" data-topicid="8518" href="/d/drug information/8518.html" rel="external">unfractionated heparin</a>) (<a class="grade" href="https://medilib.ir/uptodate/show/grade_1" rel="external">Grade 1A</a>). For patients with malignancy, we suggest prophylactic anticoagulation, especially among hospitalized patients (<a class="grade" href="https://medilib.ir/uptodate/show/grade_4" rel="external">Grade 2A</a>). It may be reasonable to administer prophylactic anticoagulation to high-risk patients in the ambulatory setting when the perceived risk of thrombosis outweighs the risk of bleeding. High-risk factors include previous venous thrombosis, bulky disease, hereditary thrombophilia, or suboptimal catheter tip location. (See <a class="local">'Thrombosis prevention'</a> above.)</p><p></p><p class="headingAnchor" id="H2224560954"><span class="h1">ACKNOWLEDGMENTS</span><span class="headingEndMark"> — </span>The editorial staff at UpToDate acknowledge Caroline Bérubé, MD, and James L Zehnder, MD, who contributed to an earlier version of this topic review. </p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Verso M, Agnelli G. Venous thromboembolism associated with long-term use of central venous catheters in cancer patients. J Clin Oncol 2003; 21:3665.</a></li><li><a class="nounderline abstract_t">Mustafa S, Stein PD, Patel KC, et al. Upper extremity deep venous thrombosis. Chest 2003; 123:1953.</a></li><li><a class="nounderline abstract_t">Flinterman LE, Van Der Meer FJ, Rosendaal FR, Doggen CJ. Current perspective of venous thrombosis in the upper extremity. J Thromb Haemost 2008; 6:1262.</a></li><li><a class="nounderline abstract_t">Samuelson B, Go AS, Sung SH, et al. Initial management and outcomes after superficial thrombophlebitis: The Cardiovascular Research Network Venous Thromboembolism study. J Hosp Med 2016; 11:432.</a></li><li><a class="nounderline abstract_t">Joffe HV, Kucher N, Tapson VF, et al. Upper-extremity deep vein thrombosis: a prospective registry of 592 patients. Circulation 2004; 110:1605.</a></li><li><a class="nounderline abstract_t">Muñoz FJ, Mismetti P, Poggio R, et al. Clinical outcome of patients with upper-extremity deep vein thrombosis: results from the RIETE Registry. Chest 2008; 133:143.</a></li><li><a class="nounderline abstract_t">Kucher N. Clinical practice. Deep-vein thrombosis of the upper extremities. N Engl J Med 2011; 364:861.</a></li><li><a class="nounderline abstract_t">Owens CA, Bui JT, Knuttinen MG, et al. Pulmonary embolism from upper extremity deep vein thrombosis and the role of superior vena cava filters: a review of the literature. J Vasc Interv Radiol 2010; 21:779.</a></li><li><a class="nounderline abstract_t">Shenoy S. Surgical anatomy of upper arm: what is needed for AVF planning. J Vasc Access 2009; 10:223.</a></li><li><a class="nounderline abstract_t">Dolmatch BL, Gurley JC, Baskin KM, et al. Society of Interventional Radiology Reporting Standards for Thoracic Central Vein Obstruction: Endorsed by the American Society of Diagnostic and Interventional Nephrology (ASDIN), British Society of Interventional Radiology (BSIR), Canadian Interventional Radiology Association (CIRA), Heart Rhythm Society (HRS), Indian Society of Vascular and Interventional Radiology (ISVIR), Vascular Access Society of the Americas (VASA), and Vascular Access Society of Britain and Ireland (VASBI). J Vasc Interv Radiol 2018; 29:454.</a></li><li><a class="nounderline abstract_t">Otten TR, Stein PD, Patel KC, et al. Thromboembolic disease involving the superior vena cava and brachiocephalic veins. Chest 2003; 123:809.</a></li><li><a class="nounderline abstract_t">Rooden CJ, Tesselaar ME, Osanto S, et al. Deep vein thrombosis associated with central venous catheters - a review. J Thromb Haemost 2005; 3:2409.</a></li><li><a class="nounderline abstract_t">Luciani A, Clement O, Halimi P, et al. Catheter-related upper extremity deep venous thrombosis in cancer patients: a prospective study based on Doppler US. Radiology 2001; 220:655.</a></li><li><a class="nounderline abstract_t">Ageno W, Haas S, Weitz JI, et al. Upper Extremity DVT versus Lower Extremity DVT: Perspectives from the GARFIELD-VTE Registry. Thromb Haemost 2019; 119:1365.</a></li><li><a class="nounderline abstract_t">Di Nisio M, Van Sluis GL, Bossuyt PM, et al. Accuracy of diagnostic tests for clinically suspected upper extremity deep vein thrombosis: a systematic review. J Thromb Haemost 2010; 8:684.</a></li><li><a class="nounderline abstract_t">Chopra V, Anand S, Hickner A, et al. Risk of venous thromboembolism associated with peripherally inserted central catheters: a systematic review and meta-analysis. Lancet 2013; 382:311.</a></li><li><a class="nounderline abstract_t">Paauw JD, Borders H, Ingalls N, et al. The incidence of PICC line-associated thrombosis with and without the use of prophylactic anticoagulants. JPEN J Parenter Enteral Nutr 2008; 32:443.</a></li><li><a class="nounderline abstract_t">Bonizzoli M, Batacchi S, Cianchi G, et al. Peripherally inserted central venous catheters and central venous catheters related thrombosis in post-critical patients. Intensive Care Med 2011; 37:284.</a></li><li><a class="nounderline abstract_t">Evans RS, Sharp JH, Linford LH, et al. Risk of symptomatic DVT associated with peripherally inserted central catheters. Chest 2010; 138:803.</a></li><li><a class="nounderline abstract_t">Trerotola SO, Stavropoulos SW, Mondschein JI, et al. Triple-lumen peripherally inserted central catheter in patients in the critical care unit: prospective evaluation. Radiology 2010; 256:312.</a></li><li><a class="nounderline abstract_t">Mino JS, Gutnick JR, Monteiro R, et al. Line-associated thrombosis as the major cause of hospital-acquired deep vein thromboses: an analysis from National Surgical Quality Improvement Program data and a call to reassess prophylaxis strategies. Am J Surg 2014; 208:45.</a></li><li><a class="nounderline abstract_t">Major KM, Bulic S, Rowe VL, et al. Internal jugular, subclavian, and axillary deep venous thrombosis and the risk of pulmonary embolism. Vascular 2008; 16:73.</a></li><li><a class="nounderline abstract_t">Saseedharan S, Bhargava S. Upper extremity deep vein thrombosis. Int J Crit Illn Inj Sci 2012; 2:21.</a></li><li><a class="nounderline abstract_t">Safdar N, Maki DG. Risk of catheter-related bloodstream infection with peripherally inserted central venous catheters used in hospitalized patients. Chest 2005; 128:489.</a></li><li><a class="nounderline abstract_t">Yukisawa S, Fujiwara Y, Yamamoto Y, et al. Upper-extremity deep vein thrombosis related to central venous port systems implanted in cancer patients. Br J Radiol 2010; 83:850.</a></li><li><a class="nounderline abstract_t">Tabatabaie O, Kasumova GG, Kent TS, et al. Upper extremity deep venous thrombosis after port insertion: What are the risk factors? Surgery 2017; 162:437.</a></li><li><a class="nounderline abstract_t">Saber W, Moua T, Williams EC, et al. Risk factors for catheter-related thrombosis (CRT) in cancer patients: a patient-level data (IPD) meta-analysis of clinical trials and prospective studies. J Thromb Haemost 2011; 9:312.</a></li><li><a class="nounderline abstract_t">Decousus H, Bourmaud A, Fournel P, et al. Cancer-associated thrombosis in patients with implanted ports: a prospective multicenter French cohort study (ONCOCIP). Blood 2018; 132:707.</a></li><li><a class="nounderline abstract_t">Jiang M, Li CL, Pan CQ, et al. Risk of venous thromboembolism associated with totally implantable venous access ports in cancer patients: A systematic review and meta-analysis. J Thromb Haemost 2020; 18:2253.</a></li><li><a class="nounderline abstract_t">Bahl A, Diloreto E, Jankowski D, et al. Comparison of 2 Midline Catheter Devices With Differing Antithrombogenic Mechanisms for Catheter-Related Thrombosis: A Randomized Clinical Trial. JAMA Netw Open 2021; 4:e2127836.</a></li><li><a class="nounderline abstract_t">Bahl A, Karabon P, Chu D. Comparison of Venous Thrombosis Complications in Midlines Versus Peripherally Inserted Central Catheters: Are Midlines the Safer Option? Clin Appl Thromb Hemost 2019; 25:1076029619839150.</a></li><li><a class="nounderline abstract_t">Chopra V, Kaatz S, Swaminathan L, et al. Variation in use and outcomes related to midline catheters: results from a multicentre pilot study. BMJ Qual Saf 2019; 28:714.</a></li><li><a class="nounderline abstract_t">Swaminathan L, Flanders S, Horowitz J, et al. Safety and Outcomes of Midline Catheters vs Peripherally Inserted Central Catheters for Patients With Short-term Indications: A Multicenter Study. JAMA Intern Med 2022; 182:50.</a></li><li><a class="nounderline abstract_t">Nifong TP, McDevitt TJ. The effect of catheter to vein ratio on blood flow rates in a simulated model of peripherally inserted central venous catheters. Chest 2011; 140:48.</a></li><li><a class="nounderline abstract_t">Wilson TJ, Brown DL, Meurer WJ, et al. Risk factors associated with peripherally inserted central venous catheter-related large vein thrombosis in neurological intensive care patients. Intensive Care Med 2012; 38:272.</a></li><li><a class="nounderline abstract_t">Sharp R, Cummings M, Fielder A, et al. The catheter to vein ratio and rates of symptomatic venous thromboembolism in patients with a peripherally inserted central catheter (PICC): a prospective cohort study. Int J Nurs Stud 2015; 52:677.</a></li><li><a class="nounderline abstract_t">Sharp R, Carr P, Childs J, et al. Catheter to vein ratio and risk of peripherally inserted central catheter (PICC)-associated thrombosis according to diagnostic group: a retrospective cohort study. BMJ Open 2021; 11:e045895.</a></li><li><a class="nounderline abstract_t">O'Brien J, Paquet F, Lindsay R, Valenti D. Insertion of PICCs with minimum number of lumens reduces complications and costs. J Am Coll Radiol 2013; 10:864.</a></li><li><a class="nounderline abstract_t">Chopra V, Ratz D, Kuhn L, et al. Peripherally inserted central catheter-related deep vein thrombosis: contemporary patterns and predictors. J Thromb Haemost 2014; 12:847.</a></li><li><a class="nounderline abstract_t">Chopra V, Flanders SA, Saint S, et al. The Michigan Appropriateness Guide for Intravenous Catheters (MAGIC): Results From a Multispecialty Panel Using the RAND/UCLA Appropriateness Method. Ann Intern Med 2015; 163:S1.</a></li><li><a class="nounderline abstract_t">Swaminathan L, Flanders S, Rogers M, et al. Improving PICC use and outcomes in hospitalised patients: an interrupted time series study using MAGIC criteria. BMJ Qual Saf 2018; 27:271.</a></li><li><a class="nounderline abstract_t">Parienti JJ, Mongardon N, Mégarbane B, et al. Intravascular Complications of Central Venous Catheterization by Insertion Site. N Engl J Med 2015; 373:1220.</a></li><li><a class="nounderline abstract_t">Winters JP, Callas PW, Cushman M, et al. Central venous catheters and upper extremity deep vein thrombosis in medical inpatients: the Medical Inpatients and Thrombosis (MITH) Study. J Thromb Haemost 2015; 13:2155.</a></li><li><a class="nounderline abstract_t">Fallouh N, McGuirk HM, Flanders SA, Chopra V. Peripherally Inserted Central Catheter-associated Deep Vein Thrombosis: A Narrative Review. Am J Med 2015; 128:722.</a></li><li><a class="nounderline abstract_t">Nitta K, Yoneyama M. Polymer concentration dependence of the helix to random coil transition of a charged polypeptide in aqueous salt solution. Biophys Chem 1975; 3:323.</a></li><li><a class="nounderline abstract_t">Grove JR, Pevec WC. Venous thrombosis related to peripherally inserted central catheters. J Vasc Interv Radiol 2000; 11:837.</a></li><li><a class="nounderline abstract_t">Liem TK, Yanit KE, Moseley SE, et al. Peripherally inserted central catheter usage patterns and associated symptomatic upper extremity venous thrombosis. J Vasc Surg 2012; 55:761.</a></li><li><a class="nounderline abstract_t">Patel GS, Jain K, Kumar R, et al. Comparison of peripherally inserted central venous catheters (PICC) versus subcutaneously implanted port-chamber catheters by complication and cost for patients receiving chemotherapy for non-haematological malignancies. Support Care Cancer 2014; 22:121.</a></li><li><a class="nounderline abstract_t">Chopra V, Anand S, Krein SL, et al. Bloodstream infection, venous thrombosis, and peripherally inserted central catheters: reappraising the evidence. Am J Med 2012; 125:733.</a></li><li><a class="nounderline abstract_t">Woller SC, Stevens SM, Jones JP, et al. Derivation and validation of a simple model to identify venous thromboembolism risk in medical patients. Am J Med 2011; 124:947.</a></li><li><a class="nounderline abstract_t">Greene MT, Flanders SA, Woller SC, et al. The Association Between PICC Use and Venous Thromboembolism in Upper and Lower Extremities. Am J Med 2015; 128:986.</a></li><li><a class="nounderline abstract_t">Chen Y, Chen H, Yang J, et al. Patterns and risk factors of peripherally inserted central venous catheter-related symptomatic thrombosis events in patients with malignant tumors receiving chemotherapy. J Vasc Surg Venous Lymphat Disord 2020; 8:919.</a></li><li><a class="nounderline abstract_t">Yuen HLA, Zhao J, Tran H, Chunilal SD. Development of a risk score to predict peripherally inserted central catheter thrombosis in active cancer. Intern Med J 2022; 52:1733.</a></li><li><a class="nounderline abstract_t">Schears GJ, Ferko N, Syed I, et al. Peripherally inserted central catheters inserted with current best practices have low deep vein thrombosis and central line-associated bloodstream infection risk compared with centrally inserted central catheters: A contemporary meta-analysis. J Vasc Access 2021; 22:9.</a></li><li><a class="nounderline abstract_t">Balsorano P, Virgili G, Villa G, et al. Peripherally inserted central catheter-related thrombosis rate in modern vascular access era-when insertion technique matters: A systematic review and meta-analysis. J Vasc Access 2020; 21:45.</a></li><li><a class="nounderline abstract_t">Brook I, Frazier EH. Aerobic and anaerobic microbiology of superficial suppurative thrombophlebitis. Arch Surg 1996; 131:95.</a></li><li><a class="nounderline abstract_t">van Rooden CJ, Schippers EF, Barge RM, et al. Infectious complications of central venous catheters increase the risk of catheter-related thrombosis in hematology patients: a prospective study. J Clin Oncol 2005; 23:2655.</a></li><li><a class="nounderline abstract_t">O'Grady NP, Alexander M, Dellinger EP, et al. Guidelines for the prevention of intravascular catheter-related infections. Centers for Disease Control and Prevention. MMWR Recomm Rep 2002; 51:1.</a></li><li><a class="nounderline abstract_t">Chopra V, Kaatz S, Conlon A, et al. The Michigan Risk Score to predict peripherally inserted central catheter-associated thrombosis. J Thromb Haemost 2017; 15:1951.</a></li><li><a class="nounderline abstract_t">Dentali F, Gianni M, Agnelli G, Ageno W. Association between inherited thrombophilic abnormalities and central venous catheter thrombosis in patients with cancer: a meta-analysis. J Thromb Haemost 2008; 6:70.</a></li><li><a class="nounderline abstract_t">Warkentin TE, Cook DJ. Current perspective of venous thrombosis in the upper extremity: a rebuttal. J Thromb Haemost 2009; 7:237.</a></li><li><a class="nounderline abstract_t">Fijnheer R, Paijmans B, Verdonck LF, et al. Factor V Leiden in central venous catheter-associated thrombosis. Br J Haematol 2002; 118:267.</a></li><li><a class="nounderline abstract_t">Leebeek FW, Stadhouders NA, van Stein D, et al. Hypercoagulability states in upper-extremity deep venous thrombosis. Am J Hematol 2001; 67:15.</a></li><li><a class="nounderline abstract_t">Riordan M, Weiden PL. Factor V Leiden mutation does not account for central venous catheter-related thrombosis. Am J Hematol 1998; 58:150.</a></li><li><a class="nounderline abstract_t">Flinterman LE, van Hylckama Vlieg A, Rosendaal FR, Doggen CJ. Venous thrombosis of the upper extremity: effect of blood group and coagulation factor levels on risk. Br J Haematol 2010; 149:118.</a></li><li><a class="nounderline abstract_t">Bhakta A, Tafen M, Ahmed M, et al. Risk of catheter-associated deep venous thrombosis in inflammatory bowel disease. Dis Colon Rectum 2014; 57:1379.</a></li><li><a class="nounderline abstract_t">Martinelli I, Battaglioli T, Bucciarelli P, et al. Risk factors and recurrence rate of primary deep vein thrombosis of the upper extremities. Circulation 2004; 110:566.</a></li><li><a class="nounderline abstract_t">Van Rooden CJ, Rosendaal FR, Meinders AE, et al. The contribution of factor V Leiden and prothrombin G20210A mutation to the risk of central venous catheter-related thrombosis. Haematologica 2004; 89:201.</a></li><li><a class="nounderline abstract_t">Hong AP, Cook DJ, Sigouin CS, Warkentin TE. Central venous catheters and upper-extremity deep-vein thrombosis complicating immune heparin-induced thrombocytopenia. Blood 2003; 101:3049.</a></li><li><a class="nounderline abstract_t">Lamontagne F, McIntyre L, Dodek P, et al. Nonleg venous thrombosis in critically ill adults: a nested prospective cohort study. JAMA Intern Med 2014; 174:689.</a></li><li><a class="nounderline abstract_t">Kastora SL, Oduyoye O, Mahmood S. Upper extremity deep venous thrombosis prevalence in the NHS Grampian Medical Ambulatory clinic: diagnostic, therapeutic, and prognostic considerations in oncology patients. Ir J Med Sci 2022; 191:1569.</a></li><li><a class="nounderline abstract_t">Cape AV, Mogensen KM, Robinson MK, Carusi DA. Peripherally inserted central catheter (PICC) complications during pregnancy. JPEN J Parenter Enteral Nutr 2014; 38:595.</a></li><li><a class="nounderline abstract_t">Jacques L, Foeller M, Farez R, et al. Safety of peripherally inserted central catheters during pregnancy: a retrospective study. J Matern Fetal Neonatal Med 2018; 31:1166.</a></li><li><a class="nounderline abstract_t">Vayá A, Mira Y, Mateo J, et al. Prothrombin G20210A mutation and oral contraceptive use increase upper-extremity deep vein thrombotic risk. Thromb Haemost 2003; 89:452.</a></li><li><a class="nounderline abstract_t">Héron E, Lozinguez O, Alhenc-Gelas M, et al. Hypercoagulable states in primary upper-extremity deep vein thrombosis. Arch Intern Med 2000; 160:382.</a></li><li><a class="nounderline abstract_t">Loret de Mola JR, Kiwi R, Austin C, Goldfarb JM. Subclavian deep vein thrombosis associated with the use of recombinant follicle-stimulating hormone (Gonal-F) complicating mild ovarian hyperstimulation syndrome. Fertil Steril 2000; 73:1253.</a></li><li><a class="nounderline abstract_t">Rao AK, Chitkara U, Milki AA. Subclavian vein thrombosis following IVF and ovarian hyperstimulation: a case report. Hum Reprod 2005; 20:3307.</a></li><li class="breakAll">Skillman JJ. Superficial phlebitis: Inflammatory, infectious associated with deep vein thrombosis. In: Decision Making in Vascular Surgery, Cronenwett JL, Rutherford RB (Eds), WB Saunders, Philadelphia 2001.</li><li><a class="nounderline abstract_t">Bern MM, Lokich JJ, Wallach SR, et al. Very low doses of warfarin can prevent thrombosis in central venous catheters. A randomized prospective trial. Ann Intern Med 1990; 112:423.</a></li><li><a class="nounderline abstract_t">Lokich JJ, Becker B. Subclavian vein thrombosis in patients treated with infusion chemotherapy for advanced malignancy. Cancer 1983; 52:1586.</a></li><li><a class="nounderline abstract_t">Haire WD, Lieberman RP, Lund GB, et al. Thrombotic complications of silicone rubber catheters during autologous marrow and peripheral stem cell transplantation: prospective comparison of Hickman and Groshong catheters. Bone Marrow Transplant 1991; 7:57.</a></li><li><a class="nounderline abstract_t">Baskin JL, Pui CH, Reiss U, et al. Management of occlusion and thrombosis associated with long-term indwelling central venous catheters. Lancet 2009; 374:159.</a></li><li><a class="nounderline abstract_t">Monreal M, Raventos A, Lerma R, et al. Pulmonary embolism in patients with upper extremity DVT associated to venous central lines--a prospective study. Thromb Haemost 1994; 72:548.</a></li><li><a class="nounderline abstract_t">Prandoni P, Polistena P, Bernardi E, et al. Upper-extremity deep vein thrombosis. Risk factors, diagnosis, and complications. Arch Intern Med 1997; 157:57.</a></li><li><a class="nounderline abstract_t">Constans J, Salmi LR, Sevestre-Pietri MA, et al. A clinical prediction score for upper extremity deep venous thrombosis. Thromb Haemost 2008; 99:202.</a></li><li><a class="nounderline abstract_t">Kleinjan A, Di Nisio M, Beyer-Westendorf J, et al. Safety and feasibility of a diagnostic algorithm combining clinical probability, d-dimer testing, and ultrasonography for suspected upper extremity deep venous thrombosis: a prospective management study. Ann Intern Med 2014; 160:451.</a></li><li><a class="nounderline abstract_t">Merminod T, Pellicciotta S, Bounameaux H. Limited usefulness of D-dimer in suspected deep vein thrombosis of the upper extremities. Blood Coagul Fibrinolysis 2006; 17:225.</a></li><li><a class="nounderline abstract_t">Di Nisio M, Squizzato A, Rutjes AW, et al. Diagnostic accuracy of D-dimer test for exclusion of venous thromboembolism: a systematic review. J Thromb Haemost 2007; 5:296.</a></li><li><a class="nounderline abstract_t">van Es N, Bleker SM, Di Nisio M, et al. A clinical decision rule and D-dimer testing to rule out upper extremity deep vein thrombosis in high-risk patients. Thromb Res 2016; 148:59.</a></li><li><a class="nounderline abstract_t">Sartori M, Migliaccio L, Favaretto E, et al. Whole-Arm Ultrasound to Rule Out Suspected Upper-Extremity Deep Venous Thrombosis in Outpatients. JAMA Intern Med 2015; 175:1226.</a></li><li><a class="nounderline abstract_t">Desjardins B, Rybicki FJ, Kim HS, et al. ACR Appropriateness Criteria® Suspected upper extremity deep vein thrombosis. J Am Coll Radiol 2012; 9:613.</a></li><li><a class="nounderline abstract_t">Baarslag HJ, van Beek EJ, Koopman MM, Reekers JA. Prospective study of color duplex ultrasonography compared with contrast venography in patients suspected of having deep venous thrombosis of the upper extremities. Ann Intern Med 2002; 136:865.</a></li><li><a class="nounderline abstract_t">Dronkers CEA, Klok FA, van Haren GR, et al. Diagnosing upper extremity deep vein thrombosis with non-contrast-enhanced Magnetic Resonance Direct Thrombus Imaging: A pilot study. Thromb Res 2018; 163:47.</a></li><li><a class="nounderline abstract_t">Baarslag HJ, Van Beek EJ, Reekers JA. Magnetic resonance venography in consecutive patients with suspected deep vein thrombosis of the upper extremity: initial experience. Acta Radiol 2004; 45:38.</a></li><li><a class="nounderline abstract_t">Stevens SM, Woller SC, Kreuziger LB, et al. Antithrombotic Therapy for VTE Disease: Second Update of the CHEST Guideline and Expert Panel Report. Chest 2021; 160:e545.</a></li><li><a class="nounderline abstract_t">Kearon C, Akl EA, Ornelas J, et al. Antithrombotic Therapy for VTE Disease: CHEST Guideline and Expert Panel Report. Chest 2016; 149:315.</a></li><li><a class="nounderline abstract_t">Kearon C, Akl EA, Comerota AJ, et al. Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141:e419S.</a></li><li><a class="nounderline abstract_t">Bauersachs R, Gerlach HE, Heinken A, et al. Management and Outcomes of Patients with Isolated Superficial Vein Thrombosis under Real Life Conditions (INSIGHTS-SVT). Eur J Vasc Endovasc Surg 2021; 62:241.</a></li><li><a class="nounderline abstract_t">Duffett L, Kearon C, Rodger M, Carrier M. Treatment of Superficial Vein Thrombosis: A Systematic Review and Meta-Analysis. Thromb Haemost 2019; 119:479.</a></li><li><a class="nounderline abstract_t">Elman EE, Kahn SR. The post-thrombotic syndrome after upper extremity deep venous thrombosis in adults: a systematic review. Thromb Res 2006; 117:609.</a></li><li><a class="nounderline abstract_t">Debourdeau P, Kassab Chahmi D, Le Gal G, et al. 2008 SOR guidelines for the prevention and treatment of thrombosis associated with central venous catheters in patients with cancer: report from the working group. Ann Oncol 2009; 20:1459.</a></li><li><a class="nounderline abstract_t">Martinelli I, Franchini M, Mannucci PM. How I treat rare venous thromboses. Blood 2008; 112:4818.</a></li><li><a class="nounderline abstract_t">Rajasekhar A, Streiff MB. How I treat central venous access device-related upper extremity deep vein thrombosis. Blood 2017; 129:2727.</a></li><li><a class="nounderline abstract_t">Debourdeau P, Farge D, Beckers M, et al. International clinical practice guidelines for the treatment and prophylaxis of thrombosis associated with central venous catheters in patients with cancer. J Thromb Haemost 2013; 11:71.</a></li><li><a class="nounderline abstract_t">Porfidia A, Agostini F, Giarretta I, et al. Upper extremity deep vein thrombosis treated with direct oral anticoagulants: a multi-center real world experience. J Thromb Thrombolysis 2020; 50:355.</a></li><li><a class="nounderline abstract_t">Montiel FS, Ghazvinian R, Gottsäter A, Elf J. Treatment with direct oral anticoagulants in patients with upper extremity deep vein thrombosis. Thromb J 2017; 15:26.</a></li><li><a class="nounderline abstract_t">Lokich JJ, Bothe A Jr, Benotti P, Moore C. Complications and management of implanted venous access catheters. J Clin Oncol 1985; 3:710.</a></li><li><a class="nounderline abstract_t">Jones MA, Lee DY, Segall JA, et al. Characterizing resolution of catheter-associated upper extremity deep venous thrombosis. J Vasc Surg 2010; 51:108.</a></li><li><a class="nounderline abstract_t">Kovacs MJ, Kahn SR, Rodger M, et al. A pilot study of central venous catheter survival in cancer patients using low-molecular-weight heparin (dalteparin) and warfarin without catheter removal for the treatment of upper extremity deep vein thrombosis (The Catheter Study). J Thromb Haemost 2007; 5:1650.</a></li><li><a class="nounderline abstract_t">Baskin JL, Reiss U, Wilimas JA, et al. Thrombolytic therapy for central venous catheter occlusion. Haematologica 2012; 97:641.</a></li><li><a class="nounderline abstract_t">da Costa ACC, Ribeiro JM, Vasques CI, et al. Interventions to obstructive long-term central venous catheter in cancer patients: a meta-analysis. Support Care Cancer 2019; 27:407.</a></li><li><a class="nounderline abstract_t">van Miert C, Hill R, Jones L. Interventions for restoring patency of occluded central venous catheter lumens. Cochrane Database Syst Rev 2012; 2012:CD007119.</a></li><li><a class="nounderline abstract_t">Kennard AL, Walters GD, Jiang SH, Talaulikar GS. Interventions for treating central venous haemodialysis catheter malfunction. Cochrane Database Syst Rev 2017; 10:CD011953.</a></li><li><a class="nounderline abstract_t">Deitcher SR, Fraschini G, Himmelfarb J, et al. Dose-ranging trial with a recombinant urokinase (urokinase alfa) for occluded central venous catheters in oncology patients. J Vasc Interv Radiol 2004; 15:575.</a></li><li><a class="nounderline abstract_t">Moll S, Kenyon P, Bertoli L, et al. Phase II trial of alfimeprase, a novel-acting fibrin degradation agent, for occluded central venous access devices. J Clin Oncol 2006; 24:3056.</a></li><li><a class="nounderline abstract_t">Horne MK 3rd, Mayo DJ. Low-dose urokinase infusions to treat fibrinous obstruction of venous access devices in cancer patients. J Clin Oncol 1997; 15:2709.</a></li><li><a class="nounderline abstract_t">Haire WD, Deitcher SR, Mullane KM, et al. Recombinant urokinase for restoration of patency in occluded central venous access devices. A double-blind, placebo-controlled trial. Thromb Haemost 2004; 92:575.</a></li><li><a class="nounderline abstract_t">Haire WD, Atkinson JB, Stephens LC, Kotulak GD. Urokinase versus recombinant tissue plasminogen activator in thrombosed central venous catheters: a double-blinded, randomized trial. Thromb Haemost 1994; 72:543.</a></li><li><a class="nounderline abstract_t">Ponec D, Irwin D, Haire WD, et al. Recombinant tissue plasminogen activator (alteplase) for restoration of flow in occluded central venous access devices: a double-blind placebo-controlled trial--the Cardiovascular Thrombolytic to Open Occluded Lines (COOL) efficacy trial. J Vasc Interv Radiol 2001; 12:951.</a></li><li><a class="nounderline abstract_t">Fink JM, Capozzi DL, Shermock KM, et al. Alteplase for central catheter clearance: 1 mg/mL versus 2 mg/2 mL. Ann Pharmacother 2004; 38:351.</a></li><li><a class="nounderline abstract_t">Semba CP, Deitcher SR, Li X, et al. Treatment of occluded central venous catheters with alteplase: results in 1,064 patients. J Vasc Interv Radiol 2002; 13:1199.</a></li><li><a class="nounderline abstract_t">Monagle P, Chan AK, Goldenberg NA, et al. Antithrombotic therapy in neonates and children: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141:e737S.</a></li><li><a class="nounderline abstract_t">Pollo V, Dionízio D, Bucuvic EM, et al. Alteplase vs. urokinase for occluded hemodialysis catheter: A randomized trial. Hemodial Int 2016; 20:378.</a></li><li><a class="nounderline abstract_t">Kumwenda M, Dougherty L, Spooner H, et al. Managing dysfunctional central venous access devices: a practical approach to urokinase thrombolysis. Br J Nurs 2018; 27:S4.</a></li><li><a class="nounderline abstract_t">Schiffer CA, Mangu PB, Wade JC, et al. Central venous catheter care for the patient with cancer: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol 2013; 31:1357.</a></li><li><a class="nounderline abstract_t">Zwicker JI, Connolly G, Carrier M, et al. Catheter-associated deep vein thrombosis of the upper extremity in cancer patients: guidance from the SSC of the ISTH. J Thromb Haemost 2014; 12:796.</a></li><li><a class="nounderline abstract_t">Kahn SR, Lim W, Dunn AS, et al. Prevention of VTE in nonsurgical patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141:e195S.</a></li><li><a class="nounderline abstract_t">Prandoni P. Prophylaxis of catheter-related thrombosis in cancer patients. Lancet 2009; 373:523.</a></li><li><a class="nounderline abstract_t">Key NS, Khorana AA, Kuderer NM, et al. Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Clinical Practice Guideline Update. J Clin Oncol 2020; 38:496.</a></li><li><a class="nounderline abstract_t">De Cicco M, Matovic M, Balestreri L, et al. Early and short-term acenocumarine or dalteparin for the prevention of central vein catheter-related thrombosis in cancer patients: a randomized controlled study based on serial venographies. Ann Oncol 2009; 20:1936.</a></li><li><a class="nounderline abstract_t">Couban S, Goodyear M, Burnell M, et al. Randomized placebo-controlled study of low-dose warfarin for the prevention of central venous catheter-associated thrombosis in patients with cancer. J Clin Oncol 2005; 23:4063.</a></li><li><a class="nounderline abstract_t">Young AM, Billingham LJ, Begum G, et al. Warfarin thromboprophylaxis in cancer patients with central venous catheters (WARP): an open-label randomised trial. Lancet 2009; 373:567.</a></li><li><a class="nounderline abstract_t">Mismetti P, Mille D, Laporte S, et al. Low-molecular-weight heparin (nadroparin) and very low doses of warfarin in the prevention of upper extremity thrombosis in cancer patients with indwelling long-term central venous catheters: a pilot randomized trial. Haematologica 2003; 88:67.</a></li><li><a class="nounderline abstract_t">Heaton DC, Han DY, Inder A. Minidose (1 mg) warfarin as prophylaxis for central vein catheter thrombosis. Intern Med J 2002; 32:84.</a></li><li><a class="nounderline abstract_t">Ruud E, Holmstrøm H, De Lange C, et al. Low-dose warfarin for the prevention of central line-associated thromboses in children with malignancies--a randomized, controlled study. Acta Paediatr 2006; 95:1053.</a></li><li><a class="nounderline abstract_t">Vidal E, Sharathkumar A, Glover J, Faustino EV. Central venous catheter-related thrombosis and thromboprophylaxis in children: a systematic review and meta-analysis. J Thromb Haemost 2014; 12:1096.</a></li><li><a class="nounderline abstract_t">Akl EA, Kamath G, Yosuico V, et al. Thromboprophylaxis for patients with cancer and central venous catheters: a systematic review and a meta-analysis. Cancer 2008; 112:2483.</a></li><li><a class="nounderline abstract_t">Cunningham MS, White B, Hollywood D, O'Donnell J. Primary thromboprophylaxis for cancer patients with central venous catheters--a reappraisal of the evidence. Br J Cancer 2006; 94:189.</a></li><li><a class="nounderline abstract_t">Kirkpatrick A, Rathbun S, Whitsett T, Raskob G. Prevention of central venous catheter-associated thrombosis: a meta-analysis. Am J Med 2007; 120:901.e1.</a></li><li><a class="nounderline abstract_t">Chaukiyal P, Nautiyal A, Radhakrishnan S, et al. Thromboprophylaxis in cancer patients with central venous catheters. A systematic review and meta-analysis. Thromb Haemost 2008; 99:38.</a></li><li><a class="nounderline abstract_t">Rawson KM, Newburn-Cook CV. The use of low-dose warfarin as prophylaxis for central venous catheter thrombosis in patients with cancer: a meta-analysis. Oncol Nurs Forum 2007; 34:1037.</a></li><li><a class="nounderline abstract_t">Carrier M, Tay J, Fergusson D, Wells PS. Thromboprophylaxis for catheter-related thrombosis in patients with cancer: a systematic review of the randomized, controlled trials. J Thromb Haemost 2007; 5:2552.</a></li><li><a class="nounderline abstract_t">Akl EA, Ramly EP, Kahale LA, et al. Anticoagulation for people with cancer and central venous catheters. Cochrane Database Syst Rev 2014; :CD006468.</a></li><li><a class="nounderline abstract_t">D'Ambrosio L, Aglietta M, Grignani G. Anticoagulation for central venous catheters in patients with cancer. N Engl J Med 2014; 371:1362.</a></li><li><a class="nounderline abstract_t">Akl EA, Vasireddi SR, Gunukula S, et al. Anticoagulation for patients with cancer and central venous catheters. Cochrane Database Syst Rev 2011; :CD006468.</a></li><li><a class="nounderline abstract_t">Lavau-Denes S, Lacroix P, Maubon A, et al. Prophylaxis of catheter-related deep vein thrombosis in cancer patients with low-dose warfarin, low molecular weight heparin, or control: a randomized, controlled, phase III study. Cancer Chemother Pharmacol 2013; 72:65.</a></li><li><a class="nounderline abstract_t">Kahale LA, Tsolakian IG, Hakoum MB, et al. Anticoagulation for people with cancer and central venous catheters. Cochrane Database Syst Rev 2018; 6:CD006468.</a></li><li><a class="nounderline abstract_t">Carrier M, Abou-Nassar K, Mallick R, et al. Apixaban to Prevent Venous Thromboembolism in Patients with Cancer. N Engl J Med 2019; 380:711.</a></li></ol></div><div id="topicVersionRevision">Topic 8195 Version 44.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14512399" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Venous thromboembolism associated with long-term use of central venous catheters in cancer patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12796173" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Upper extremity deep venous thrombosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18485082" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Current perspective of venous thrombosis in the upper extremity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27253585" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Initial management and outcomes after superficial thrombophlebitis: The Cardiovascular Research Network Venous Thromboembolism study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15353493" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Upper-extremity deep vein thrombosis: a prospective registry of 592 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17925416" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Clinical outcome of patients with upper-extremity deep vein thrombosis: results from the RIETE Registry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21366477" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Clinical practice. Deep-vein thrombosis of the upper extremities.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20434365" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Pulmonary embolism from upper extremity deep vein thrombosis and the role of superior vena cava filters: a review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19916160" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Surgical anatomy of upper arm: what is needed for AVF planning.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29503236" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Society of Interventional Radiology Reporting Standards for Thoracic Central Vein Obstruction: Endorsed by the American Society of Diagnostic and Interventional Nephrology (ASDIN), British Society of Interventional Radiology (BSIR), Canadian Interventional Radiology Association (CIRA), Heart Rhythm Society (HRS), Indian Society of Vascular and Interventional Radiology (ISVIR), Vascular Access Society of the Americas (VASA), and Vascular Access Society of Britain and Ireland (VASBI).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12628882" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Thromboembolic disease involving the superior vena cava and brachiocephalic veins.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15975139" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Deep vein thrombosis associated with central venous catheters - a review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11526263" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Catheter-related upper extremity deep venous thrombosis in cancer patients: a prospective study based on Doppler US.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31183844" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Upper Extremity DVT versus Lower Extremity DVT: Perspectives from the GARFIELD-VTE Registry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20141579" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Accuracy of diagnostic tests for clinically suspected upper extremity deep vein thrombosis: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23697825" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Risk of venous thromboembolism associated with peripherally inserted central catheters: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18596317" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : The incidence of PICC line-associated thrombosis with and without the use of prophylactic anticoagulants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20857280" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Peripherally inserted central venous catheters and central venous catheters related thrombosis in post-critical patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20923799" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Risk of symptomatic DVT associated with peripherally inserted central catheters.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20574104" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Triple-lumen peripherally inserted central catheter in patients in the critical care unit: prospective evaluation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24530041" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Line-associated thrombosis as the major cause of hospital-acquired deep vein thromboses: an analysis from National Surgical Quality Improvement Program data and a call to reassess prophylaxis strategies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18377835" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Internal jugular, subclavian, and axillary deep venous thrombosis and the risk of pulmonary embolism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22624098" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Upper extremity deep vein thrombosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16100130" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Risk of catheter-related bloodstream infection with peripherally inserted central venous catheters used in hospitalized patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20223904" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Upper-extremity deep vein thrombosis related to central venous port systems implanted in cancer patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28535970" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Upper extremity deep venous thrombosis after port insertion: What are the risk factors?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21040443" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Risk factors for catheter-related thrombosis (CRT) in cancer patients: a patient-level data (IPD) meta-analysis of clinical trials and prospective studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29980524" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Cancer-associated thrombosis in patients with implanted ports: a prospective multicenter French cohort study (ONCOCIP).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32479699" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Risk of venous thromboembolism associated with totally implantable venous access ports in cancer patients: A systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34613402" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Comparison of 2 Midline Catheter Devices With Differing Antithrombogenic Mechanisms for Catheter-Related Thrombosis: A Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30909723" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Comparison of Venous Thrombosis Complications in Midlines Versus Peripherally Inserted Central Catheters: Are Midlines the Safer Option?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30886119" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Variation in use and outcomes related to midline catheters: results from a multicentre pilot study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34842905" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Safety and Outcomes of Midline Catheters vs Peripherally Inserted Central Catheters for Patients With Short-term Indications: A Multicenter Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21349931" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : The effect of catheter to vein ratio on blood flow rates in a simulated model of peripherally inserted central venous catheters.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22113818" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Risk factors associated with peripherally inserted central venous catheter-related large vein thrombosis in neurological intensive care patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25593110" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : The catheter to vein ratio and rates of symptomatic venous thromboembolism in patients with a peripherally inserted central catheter (PICC): a prospective cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34226216" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Catheter to vein ratio and risk of peripherally inserted central catheter (PICC)-associated thrombosis according to diagnostic group: a retrospective cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24075218" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Insertion of PICCs with minimum number of lumens reduces complications and costs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24612469" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Peripherally inserted central catheter-related deep vein thrombosis: contemporary patterns and predictors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26369828" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : The Michigan Appropriateness Guide for Intravenous Catheters (MAGIC): Results From a Multispecialty Panel Using the RAND/UCLA Appropriateness Method.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29133462" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Improving PICC use and outcomes in hospitalised patients: an interrupted time series study using MAGIC criteria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26398070" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Intravascular Complications of Central Venous Catheterization by Insertion Site.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26340226" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Central venous catheters and upper extremity deep vein thrombosis in medical inpatients: the Medical Inpatients and Thrombosis (MITH) Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25697969" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Peripherally Inserted Central Catheter-associated Deep Vein Thrombosis: A Narrative Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/96" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Polymer concentration dependence of the helix to random coil transition of a charged polypeptide in aqueous salt solution.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10928518" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Venous thrombosis related to peripherally inserted central catheters.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22370026" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Peripherally inserted central catheter usage patterns and associated symptomatic upper extremity venous thrombosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24005884" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Comparison of peripherally inserted central venous catheters (PICC) versus subcutaneously implanted port-chamber catheters by complication and cost for patients receiving chemotherapy for non-haematological malignancies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22840660" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Bloodstream infection, venous thrombosis, and peripherally inserted central catheters: reappraising the evidence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21962315" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Derivation and validation of a simple model to identify venous thromboembolism risk in medical patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25940453" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : The Association Between PICC Use and Venous Thromboembolism in Upper and Lower Extremities.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32205131" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Patterns and risk factors of peripherally inserted central venous catheter-related symptomatic thrombosis events in patients with malignant tumors receiving chemotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34613657" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Development of a risk score to predict peripherally inserted central catheter thrombosis in active cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32356479" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Peripherally inserted central catheters inserted with current best practices have low deep vein thrombosis and central line-associated bloodstream infection risk compared with centrally inserted central catheters: A contemporary meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31177939" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Peripherally inserted central catheter-related thrombosis rate in modern vascular access era-when insertion technique matters: A systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8546586" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Aerobic and anaerobic microbiology of superficial suppurative thrombophlebitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15837979" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Infectious complications of central venous catheters increase the risk of catheter-related thrombosis in hematology patients: a prospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12233868" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Guidelines for the prevention of intravascular catheter-related infections. Centers for Disease Control and Prevention.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28796444" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : The Michigan Risk Score to predict peripherally inserted central catheter-associated thrombosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17988232" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Association between inherited thrombophilic abnormalities and central venous catheter thrombosis in patients with cancer: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19130658" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Current perspective of venous thrombosis in the upper extremity: a rebuttal.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12100159" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Factor V Leiden in central venous catheter-associated thrombosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11279652" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Hypercoagulability states in upper-extremity deep venous thrombosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9625586" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Factor V Leiden mutation does not account for central venous catheter-related thrombosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20096009" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Venous thrombosis of the upper extremity: effect of blood group and coagulation factor levels on risk.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25380003" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Risk of catheter-associated deep venous thrombosis in inflammatory bowel disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15262837" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Risk factors and recurrence rate of primary deep vein thrombosis of the upper extremities.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15003896" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : The contribution of factor V Leiden and prothrombin G20210A mutation to the risk of central venous catheter-related thrombosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12506031" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Central venous catheters and upper-extremity deep-vein thrombosis complicating immune heparin-induced thrombocytopenia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24638843" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Nonleg venous thrombosis in critically ill adults: a nested prospective cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34515987" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Upper extremity deep venous thrombosis prevalence in the NHS Grampian Medical Ambulatory clinic: diagnostic, therapeutic, and prognostic considerations in oncology patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23715775" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Peripherally inserted central catheter (PICC) complications during pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28413891" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Safety of peripherally inserted central catheters during pregnancy: a retrospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12624627" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Prothrombin G20210A mutation and oral contraceptive use increase upper-extremity deep vein thrombotic risk.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10668841" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Hypercoagulable states in primary upper-extremity deep vein thrombosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10917745" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Subclavian deep vein thrombosis associated with the use of recombinant follicle-stimulating hormone (Gonal-F) complicating mild ovarian hyperstimulation syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16085662" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Subclavian vein thrombosis following IVF and ovarian hyperstimulation: a case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16085662" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Subclavian vein thrombosis following IVF and ovarian hyperstimulation: a case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2178534" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Very low doses of warfarin can prevent thrombosis in central venous catheters. A randomized prospective trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6616416" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Subclavian vein thrombosis in patients treated with infusion chemotherapy for advanced malignancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1675136" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Thrombotic complications of silicone rubber catheters during autologous marrow and peripheral stem cell transplantation: prospective comparison of Hickman and Groshong catheters.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19595350" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Management of occlusion and thrombosis associated with long-term indwelling central venous catheters.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7878630" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Pulmonary embolism in patients with upper extremity DVT associated to venous central lines--a prospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8996041" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Upper-extremity deep vein thrombosis. Risk factors, diagnosis, and complications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18217155" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : A clinical prediction score for upper extremity deep venous thrombosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24687068" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Safety and feasibility of a diagnostic algorithm combining clinical probability, d-dimer testing, and ultrasonography for suspected upper extremity deep venous thrombosis: a prospective management study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16575263" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Limited usefulness of D-dimer in suspected deep vein thrombosis of the upper extremities.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17155963" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Diagnostic accuracy of D-dimer test for exclusion of venous thromboembolism: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27815967" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : A clinical decision rule and D-dimer testing to rule out upper extremity deep vein thrombosis in high-risk patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25961734" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Whole-Arm Ultrasound to Rule Out Suspected Upper-Extremity Deep Venous Thrombosis in Outpatients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22954541" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : ACR Appropriateness Criteria®Suspected upper extremity deep vein thrombosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12069560" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Prospective study of color duplex ultrasonography compared with contrast venography in patients suspected of having deep venous thrombosis of the upper extremities.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29353683" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Diagnosing upper extremity deep vein thrombosis with non-contrast-enhanced Magnetic Resonance Direct Thrombus Imaging: A pilot study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15164777" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Magnetic resonance venography in consecutive patients with suspected deep vein thrombosis of the upper extremity: initial experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34352278" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Antithrombotic Therapy for VTE Disease: Second Update of the CHEST Guideline and Expert Panel Report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26867832" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Antithrombotic Therapy for VTE Disease: CHEST Guideline and Expert Panel Report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22315268" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34210599" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Management and Outcomes of Patients with Isolated Superficial Vein Thrombosis under Real Life Conditions (INSIGHTS-SVT).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30716777" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Treatment of Superficial Vein Thrombosis: A Systematic Review and Meta-Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16002126" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : The post-thrombotic syndrome after upper extremity deep venous thrombosis in adults: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19525362" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : 2008 SOR guidelines for the prevention and treatment of thrombosis associated with central venous catheters in patients with cancer: report from the working group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18805965" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : How I treat rare venous thromboses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28373261" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : How I treat central venous access device-related upper extremity deep vein thrombosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23217208" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : International clinical practice guidelines for the treatment and prophylaxis of thrombosis associated with central venous catheters in patients with cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32008208" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Upper extremity deep vein thrombosis treated with direct oral anticoagulants: a multi-center real world experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29026346" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Treatment with direct oral anticoagulants in patients with upper extremity deep vein thrombosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3923161" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Complications and management of implanted venous access catheters.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19879094" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Characterizing resolution of catheter-associated upper extremity deep venous thrombosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17488349" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : A pilot study of central venous catheter survival in cancer patients using low-molecular-weight heparin (dalteparin) and warfarin without catheter removal for the treatment of upper extremity deep vein thrombosis (The Catheter Study).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22180420" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : Thrombolytic therapy for central venous catheter occlusion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30370471" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : Interventions to obstructive long-term central venous catheter in cancer patients: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22513946" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : Interventions for restoring patency of occluded central venous catheter lumens.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29106711" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : Interventions for treating central venous haemodialysis catheter malfunction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15178717" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : Dose-ranging trial with a recombinant urokinase (urokinase alfa) for occluded central venous catheters in oncology patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16809729" id="rid114" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>115 : Phase II trial of alfimeprase, a novel-acting fibrin degradation agent, for occluded central venous access devices.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9215844" id="rid115" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>116 : Low-dose urokinase infusions to treat fibrinous obstruction of venous access devices in cancer patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15351854" id="rid116" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>117 : Recombinant urokinase for restoration of patency in occluded central venous access devices. A double-blind, placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7878629" id="rid117" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>118 : Urokinase versus recombinant tissue plasminogen activator in thrombosed central venous catheters: a double-blinded, randomized trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11487675" id="rid118" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>119 : Recombinant tissue plasminogen activator (alteplase) for restoration of flow in occluded central venous access devices: a double-blind placebo-controlled trial--the Cardiovascular Thrombolytic to Open Occluded Lines (COOL) efficacy trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14742778" id="rid119" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>120 : Alteplase for central catheter clearance: 1 mg/mL versus 2 mg/2 mL.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12471182" id="rid120" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>121 : Treatment of occluded central venous catheters with alteplase: results in 1,064 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22315277" id="rid121" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>122 : Antithrombotic therapy in neonates and children: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26851872" id="rid122" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>123 : Alteplase vs. urokinase for occluded hemodialysis catheter: A randomized trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29368572" id="rid123" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>124 : Managing dysfunctional central venous access devices: a practical approach to urokinase thrombolysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23460705" id="rid124" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>125 : Central venous catheter care for the patient with cancer: American Society of Clinical Oncology clinical practice guideline.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24548519" id="rid125" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>126 : Catheter-associated deep vein thrombosis of the upper extremity in cancer patients: guidance from the SSC of the ISTH.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22315261" id="rid126" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>127 : Prevention of VTE in nonsurgical patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19217973" id="rid127" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>128 : Prophylaxis of catheter-related thrombosis in cancer patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31381464" id="rid128" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>129 : Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Clinical Practice Guideline Update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19567452" id="rid129" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>130 : Early and short-term acenocumarine or dalteparin for the prevention of central vein catheter-related thrombosis in cancer patients: a randomized controlled study based on serial venographies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15767639" id="rid130" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>131 : Randomized placebo-controlled study of low-dose warfarin for the prevention of central venous catheter-associated thrombosis in patients with cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19217991" id="rid131" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>132 : Warfarin thromboprophylaxis in cancer patients with central venous catheters (WARP): an open-label randomised trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12551829" id="rid132" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>133 : Low-molecular-weight heparin (nadroparin) and very low doses of warfarin in the prevention of upper extremity thrombosis in cancer patients with indwelling long-term central venous catheters: a pilot randomized trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11885848" id="rid133" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>134 : Minidose (1 mg) warfarin as prophylaxis for central vein catheter thrombosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16938749" id="rid134" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>135 : Low-dose warfarin for the prevention of central line-associated thromboses in children with malignancies--a randomized, controlled study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24801495" id="rid135" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>136 : Central venous catheter-related thrombosis and thromboprophylaxis in children: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18404702" id="rid136" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>137 : Thromboprophylaxis for patients with cancer and central venous catheters: a systematic review and a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16404436" id="rid137" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>138 : Primary thromboprophylaxis for cancer patients with central venous catheters--a reappraisal of the evidence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17904462" id="rid138" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>139 : Prevention of central venous catheter-associated thrombosis: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18217132" id="rid139" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>140 : Thromboprophylaxis in cancer patients with central venous catheters. A systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17878131" id="rid140" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>141 : The use of low-dose warfarin as prophylaxis for central venous catheter thrombosis in patients with cancer: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18034768" id="rid141" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>142 : Thromboprophylaxis for catheter-related thrombosis in patients with cancer: a systematic review of the randomized, controlled trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25318061" id="rid142" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>143 : Anticoagulation for people with cancer and central venous catheters.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25271618" id="rid143" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>144 : Anticoagulation for central venous catheters in patients with cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21491394" id="rid144" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>145 : Anticoagulation for patients with cancer and central venous catheters.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23636449" id="rid145" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>146 : Prophylaxis of catheter-related deep vein thrombosis in cancer patients with low-dose warfarin, low molecular weight heparin, or control: a randomized, controlled, phase III study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29856471" id="rid146" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>147 : Anticoagulation for people with cancer and central venous catheters.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30511879" id="rid147" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>148 : Apixaban to Prevent Venous Thromboembolism in Patients with Cancer.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
